

EXHIBIT 1 TO PROPOSED PRETRIAL ORDER

[PROPOSED] STATEMENT OF UNCONTESTED FACTS

For the purposes of this action only, the parties agree and stipulate to the following statements of fact for which no evidence needs to be presented at trial.

I. Procedural Background

A. The Parties

1. Plaintiff Smith Kline & French Laboratories Limited is a private limited company organized under the laws of England with a registered office at 980 Great West Road, Brentford, Middlesex, TW8 9GS.

2. In 2000, after GlaxoSmithKline plc acquired its corporate parent SmithKline Beecham plc, Smith Kline & French Laboratories Limited began doing business as GlaxoSmithKline ("GSK").

3. Plaintiff SmithKline Beecham Corporation is a Pennsylvania corporation having a place of business at One Franklin Plaza, Philadelphia, Pennsylvania, 19102.

4. In 1989, SmithKline Beckman changed its name to SmithKline Beecham Corporation. In 2000, after GlaxoSmithKline plc acquired its corporate parent SmithKline Beecham plc, SmithKline Beecham Corporation began doing business as GlaxoSmithKline ("GSK").

5. Defendant Teva Pharmaceuticals USA, Inc. is a corporation organized under the laws of Delaware having a place of business at 1090 Horsham Road, North Wales, Pennsylvania 19454.

B. Jurisdiction and Venue

6. This Court has jurisdiction over Plaintiffs' claims and Defendant's counterclaims pursuant to 28 U.S.C. §§ 1331, 1338(a), 2201, and 2202.

EXHIBIT 1 TO PROPOSED PRETRIAL ORDER

7. Venue is proper in this judicial district pursuant to 28 U.S.C. §§ 1391(b) and 1400(b).

8. The Court has personal jurisdiction over the parties.

II. Plaintiffs' Patents and Branded REQUIP® Product.

9. Plaintiff GSK markets a drug called REQUIP. The active ingredient in REQUIP is ropinirole hydrochloride.

10. REQUIP has two FDA approved indications of use: (1) treatment of the signs and symptoms of idiopathic Parkinson's disease ("PD") and (2) treatment of moderate-to-severe primary Restless Legs Syndrome ("RLS"). REQUIP has been approved by the U.S. Food and Drug Administration ("FDA") for treating the signs and symptoms of PD since 1997, and RLS since 2005. The FDA granted "priority review" status to GSK's application for approval of REQUIP for RLS.

11. GSK has caused the '808 and '860 patents to be listed in the FDA Center for Drug Evaluation and Research Approved Drug Products with Therapeutic Equivalence Evaluations ("the Orange Book") for Requip.

III. Teva's ANDA With Paragraph IV Certification

12. Teva filed an ANDA seeking approval to market a generic version of REQUIP for treatment of the signs and symptoms of idiopathic PD. Teva certified pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) that the two patents listed by GSK in the Orange Book for REQUIP—the '808 and '860 patents—were "invalid or would not be infringed." The active ingredient in Teva's generic version of REQUIP is ropinirole hydrochloride. Teva's product is bioequivalent to REQUIP.

EXHIBIT 1 TO PROPOSED PRETRIAL ORDER

13. Teva timely provided notice to GSK ("Teva's Notice Letter"), pursuant to 21 U.S.C. §§ 355(j)(2)(B) and 505(j)(2)(B)(ii), that it had filed its ANDA and provided a statement of why it believed that the '808 and '860 patents were not infringed and/or were invalid.

14. On April 6, 2005, GSK timely filed this lawsuit for infringement of the '808 and '860 patents within 45 days of receipt of Teva's Notice Letter.

15. The only claims asserted by GSK to be infringed by Teva are claim 5 of the '808 patent and claim 3 of the '860 patent.

16. Teva's submission of its ANDA constituted an act of infringement of claim 5 of the '808 patent and claim 3 of the '860 patent to the extent those claims are valid and enforceable.

IV. The Patents-In-Suit

17. U.S. Patent Application No. 06/447,564 was filed on December 7, 1982 and issued on June 5, 1984 as the '808 patent.

18. The '808 patent identifies Gregory Gallagher, Jr. as its sole inventor, and is assigned on its face to SmithKline Beckman Corporation.

19. U.S. Patent Application No 07/196,653 was filed on May 19, 1988 and issued on April 25, 1989 as the '860 patent.

20. The '860 patent claims priority under 35 U.S.C. § 119 to U.K. Patent Application No. 8712073, filed May 21, 1987.

21. The '860 patent identifies David A. A. Owen as its sole inventor, and is assigned on its face to SmithKline & French Laboratories.

EXHIBIT 1 TO PROPOSED PRETRIAL ORDER

22. The following terms used in the claims of the '860 patent have been construed as follows:

<u>Claim Term of the '860 Patent</u>	Construction
1. "administering" (Claims 1-3)	"giving a therapeutic agent to a subject to be treated"
2. "effective non-toxic amount" (Claims 1-3)	"a non-toxic amount that is effective to treat conditions of Parkinson's disease in a human being"
3. "a subject in need thereof" (Claims 1-3)	"a human with Parkinson's disease"

23. Plaintiffs are the owners of the '808 and '860 patents, without prejudice to Teva's defenses and counterclaims that implicate improper inventorship of those patents.

EXHIBIT 2 TO PROPOSED PRETRIAL ORDER

GSK'S STATEMENT OF CONTESTED ISSUES OF FACT¹

I. United States Patent No. 4,452,808 ('808 Patent)

A. Obviousness Under 35 U.S.C. § 103

1. Whether the subject matter of claim 3 of the '808 Patent would have been obvious to one of ordinary skill in the art at the time of the invention in view of the prior art references under the test set forth in *Graham v. John Deere*, 383 U.S. 1, 17 (1966).

B. Inequitable Conduct

2. Whether any person with a duty to disclose made material omissions or misstatements during the prosecution of the '808 Patent, with the intent to deceive the PTO, regarding the following issues:

- inventorship of the genus claims;
- failure to disclose the alleged prior art article Cannon, J.G., Demopoulos, B.J., Long, J.P., Flynn, J.R., and Sharabi, F.M., "*Proposed Dopaminergic Pharmacophore of Lergotrile, Pergolide, and Related Ergot Alkaloid Derivatives*," J. Med. Chem. – Communications to the Editor, 1981, Vol. 24: 238-240 (1981);
- the statement at col. 4, lines 50-52 that ropinirole hydrochloride "did not cause tachyphylaxis in the latter preparation as did its 7-hydroxy congener of the prior art;"
- the statement at col. 5, line 67 – col. 6, line 5 that "For an average size human using 4-(2-di-n-propylaminoethyl)-2(3H)-indolone hydrochloride as an active

¹ GSK's listing of "contested issues of fact" is not a concession that there is any genuine dispute with respect to the recited facts.

EXHIBIT 2 TO PROPOSED PRETRIAL ORDER

ingredient, a typical dose to show anti-hypertensive activity would be selected from the range of from about 100-250 mg of base equivalent for each dosage unit which is adapted for oral administration and which is administered orally from 1-4 times daily.”

II. United States Patent No. 4,824,860 (‘860 Patent)

A. Anticipation Under 35 U.S.C. § 102

3. Whether the ‘808 patent discloses all the limitations of claim 5 of the ‘860 Patent.

B. Obviousness Under 35 U.S.C. § 103

4. Whether the subject matter of claim 5 of the ‘860 Patent would have been obvious to one of ordinary skill in the art at the time of the invention in view of the prior art references under the test set forth in *Graham v. John Deere*, 383 U.S. 1, 17 (1966).

C. Derivation Under 35 U.S.C. § 102(f)

5. Whether the subject matter of claim 5 of the ‘860 Patent is invalid as derived from the work of Bradford University researchers.

D. Inequitable Conduct

6. Whether any person with a duty to disclose made material omissions or misstatements during the prosecution of the ‘860 Patent, with the intent to deceive the PTO, regarding the following issues:

- inventorship;
- the characterization of the prior art bromocriptine compound as a “post-synaptic dopamine agonist()” at col. 1, lines 36-39, and the failure to disclose alleged prior art article related thereto, Robert M. DeMarinis, *et al.*, “Syntheses and In-Vitro Evaluation of 4-(2-Aminoethyl)-2(3H)-indolones and Related Compounds as

EXHIBIT 2 TO PROPOSED PRETRIAL ORDER

Peripheral Prejunctional Dopamine Receptor Agonists,” J. Med. Chem. 29:939-947 (1986).

EXHIBIT 3 TO PROPOSED PRETRIAL ORDER

TEVA'S STATEMENT OF CONTESTED ISSUES OF FACT

I. United States Patent No. 4,4512,808 ('808 Patent)

A. Obviousness Under 35 U.S.C. § 103

1. Whether the subject matter of claim 3 of the '808 patent would have been obvious to one of ordinary skill in the art at the time of the invention in view of the prior art references and knowledge in the field under the test set forth in *Graham v. John Deere*, 383 U.S. 1, 17 (1966).

B. Unenforceability For Inequitable Conduct

2. Whether the following material omissions or misstatements occurred during the prosecution of the '808 patent:

- a. Whether any individual who had or should have had a duty to disclose information to the PTO under 37 C.F.R. § 1.56 knowingly failed to disclose the proper inventors for the '808 Patent;
- b. Whether any individual who had or should have had a duty to disclose information to the PTO under 37 C.F.R. § 1.56 knowingly failed to disclose material prior art and information to the PTO of which they were aware during the prosecution of the '808 patent;
- c. Whether any individual who had or should have had a duty to disclose information to the PTO under 37 C.F.R. § 1.56 knowingly made incorrect and/or misleading statements and representations in the '808 patent.

3. Whether any or all of the above material omissions and/or misstatements were made with an intent to deceive the PTO.

4. Whether the '808 patent is unenforceable for inequitable conduct.

EXHIBIT 3 TO PROPOSED PRETRIAL ORDER

III. United States Patent No. 4,824,860 ('860 Patent)

A. Anticipation Under 35 U.S.C. § 102

5. Whether the prior art discloses all the limitations of claim 5 of the '860 patent expressly or inherently.

B. Obviousness Under 35 U.S.C. § 103

6. Whether the subject matter of claim 5 of the '860 patent would have been obvious to one of ordinary skill in the art at the time of the invention in view of the prior art references and knowledge in the field under the test set forth in *Graham v. John Deere*, 383 U.S. 1, 17 (1966).

C. Derivation Under 35 U.S.C. § 102(f)

7. Whether the subject matter of claim 5 of the '860 patent is invalid as derived from the work of [REDACTED].

8. Whether the subject matter of claim 5 of the '860 patent is invalid for failure to identify the proper inventors of the claim because the subject matter is derived from the work of [REDACTED]

D. Unenforceability For Inequitable Conduct

9. Whether the following material omissions or misstatements occurred during the prosecution of the '808 patent:

- a. Whether any individual who had or should have had a duty to disclose information to the PTO under 37 C.F.R. § 1.56 knowingly failed to disclose the proper inventors for the '860 patent;
- b. Whether any individual who had or should have had a duty to disclose information to the PTO under 37 C.F.R. § 1.56 knowingly failed to

EXHIBIT 3 TO PROPOSED PRETRIAL ORDER

disclose material prior art and information to the PTO of which they were aware during the prosecution of the '860 patent;

- c. Whether any individual who had or should have had a duty to disclose information to the PTO under 37 C.F.R. § 1.56 knowingly made incorrect and/or misleading statements and representations in the '860 patent.

10. Whether any or all of the above material omissions and/or misstatements were made with an intent to deceive the PTO.

11. Whether the '860 Patent is unenforceable for inequitable conduct.

EXHIBIT 4 TO PROPOSED PRETRIAL ORDER

GSK'S STATEMENT OF CONTESTED ISSUES OF LAW

- I. To the extent that GSK's Statement of Contested Issues of Fact includes mixed issues of fact and law, or issues properly considered issues of law, GSK incorporates by reference its Statement of Contested Issues of Fact herein.
- II. Whether Teva has carried its burden of proving, by clear and convincing evidence, that the invention claimed in claim 5 of the '808 patent is invalid as obvious to one of ordinary skill in the art at the time of invention, in view of the prior art, without hindsight, and including secondary considerations of non-obviousness, under the test set forth in *Graham v. John Deere*, 383 U.S. 1, 17 (1966).
- III. Whether Teva has carried its burden of proving, by clear and convincing evidence, that a person with a duty to disclose made material misstatements or omissions in the course of obtaining the '808 patent, with the intent to deceive the PTO.
- IV. Whether Teva has carried its burden of proving, by clear and convincing evidence, that the '808 patent is unenforceable due to alleged inequitable conduct.
- V. Whether Teva has carried its burden of proving, by clear and convincing evidence, that the invention claimed in Claim 3 of the '860 patent is invalid as anticipated under 35 U.S.C. § 102.
- VI. Whether Teva has carried its burden of proving, by clear and convincing evidence, that the invention claimed in Claim 3 of the '860 patent is invalid as obvious to one of ordinary skill in the art at the time of invention, in view of the prior art, without hindsight, and including secondary considerations of non-obviousness, under the test set forth in *Graham v. John Deere*, 383 U.S. 1, 17 (1966).
- VII. Whether Teva has carried its burden of proving, by clear and convincing evidence, that the '860 patent is invalid as derived from the work of researchers at Bradford University.
- VIII. Whether Teva has carried its burden of proving, by clear and convincing evidence, that a person with a duty to disclose made material misstatements or omissions in the course of obtaining the '860 patent, with the intent to deceive the PTO.
- IX. Whether Teva has carried its burden of proving, by clear and convincing evidence, that the '860 patent is unenforceable due to alleged inequitable conduct.
- X. Whether this case is exceptional such that GSK is entitled to its reasonable attorneys fees and costs under 35 U.S.C. §285.

EXHIBIT 5 TO PROPOSED PRETRIAL ORDER

TEVA'S STATEMENT OF CONTESTED ISSUES OF LAW

1. To the extent Teva's Statement Of Contested Issues Of Fact includes mixed issues of law and fact or issues properly considered issues of law, Teva incorporates by reference its Statement Of Contested Issues Of Fact, including:

- a. Whether the subject matter of claim 5 of the '808 Patent would have been obvious to one of ordinary skill in the art at the time of the invention in view of the relevant underlying factual determinations pursuant to *Graham v. John Deere*, 383 U.S. 1, 17 (1966).
- b. Whether the inventorship of the claims of the '808 patent is correct in view of the relevant underlying factual determinations.
- c. Whether claims 1 and 8 of the '808 patent are enabled and have been shown to have utility in view of the relevant underlying factual determinations.
- d. Whether the '808 patent is unenforceable as a result of GSK's inequitable conduct in prosecuting the patent. *Bristol-Myers Squibb Co. v. Rhone-Poulenc Rorer, Inc.*, 1226, 1233-34 (Fed. Cir. 2003).
- e. Whether the subject matter of claim 3 of the '860 Patent would have been obvious to one of ordinary skill in the art at the time of the invention in view of the relevant underlying factual determinations pursuant to *Graham v. John Deere*, 383 U.S. 1, 17 (1966).
- f. Whether the inventorship of the claims of the '860 Patent is correct in view of the relevant underlying factual determinations.

EXHIBIT 5 TO PROPOSED PRETRIAL ORDER

- g. Whether claim 1 of the '860 patent is enabled and has been shown to have utility in view of the relevant underlying factual determinations.
 - h. Whether the '860 patent is unenforceable as a result of GSK's inequitable conduct in prosecuting the patent. *Bristol-Myers Squibb Co. v. Rhone-Poulenc Rorer, Inc.*, 1226, 1233-34 (Fed. Cir. 2003).
2. Whether this case is exceptional and whether Teva is entitled to its fees and costs pursuant to 35 U.S.C. § 285 and related statutes.

PROPOSED PRETRIAL ORDER EXHIBIT 7
GSK'S EXHIBIT LIST

GSK reserves the right to supplement this exhibit list as circumstances warrant, including as a result of ongoing expert discovery.

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Dates	Ending Dates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 1	GSK-REQ 026002	GSK-REQ 026551	8/17/1976 - 8/2/1978	Laboratory Notebook No. 8801	DX 46
PTX 2	GSK-REQ 098179	GSK-REQ 098333	10/28/80 - 8/17/1982	Laboratory Notebook No. 10528	
PTX 3	GSK-REQ 096872	GSK-REQ 096992	4/24/1981 - 7/14/1982	Laboratory Notebook No. 11062	
PTX 4	GSK-REQ 026552	GSK-REQ 027156	9/25/1981 - 12/27/1983	Laboratory Notebook No. 10983	DX 45
PTX 5	GSK-REQ 004689	GSK-REQ 004697	12/31/1981	Prejunctional Dopaminergic Activity of SK&F 89124-C	
PTX 6	GSK-REQ 097492	GSK-REQ 097630	5/14/1982 - 1/4/1983	Laboratory Notebook No. 11862	
PTX 7	GSK-REQ 098459	GSK-REQ 098575	8/3/1982 - 7/28/1983	Laboratory Notebook No. 11981	
PTX 8	GSK-REQ 023535	GSK-REQ 023536	8/12/1982	Biological Research : Report No. 8203177: Caudate Adenylate Cyclase Activity II	
PTX 9	GSK-REQ 013586	GSK-REQ 013588	8/13/1982	Memorandum from J. Paul Hieble to Antihypertensive Team re: August 10, 1982 Team Meeting	
PTX 10	GSK-REQ 024341	GSK-REQ 024345	8/25/1982	Biological Research : Report No. 8203836: Dose Range	

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 11	GSK-REQ 011577	GSK-REQ 011578	12/6/1982	Declaration and Power of Attorney for '808 Patent	DX 44
PTX 12	GSK-REQ 094320	GSK-REQ 094320	12/6/1982	Assignment for '808 Patent	
PTX 13	GSK-REQ 014577	GSK-REQ 014584	12/7/1982	U.S. Patent No. 4,452,808	DX 42; PX 16
PTX 14	GSK-REQ 094317	GSK-REQ 094433	12/7/1982 - 08/16/1985	Prosecution History for '808 Patent	
PTX 15	GSK-REQ 007047	GSK-REQ 007049	7/1/1983	4-(Aminoalkyl)-7-hydroxy-2(3H)-indolones, a Novel Class of Potent Presynaptic Dopamine Receptor Agonists July 1983 Communication to the Editor of the Journal of Medicinal Chemistry concerning the '944 invention	DX 64
PTX 16	GSK-REQ 007068	GSK-REQ 007069	8/21/1984	Poster Session, Adrenergic Pharmacology The Pharmacologist Abstracts Program August '84, Volume 26 - Number 3	DX 103 (2nd page)
PTX 17	GSK-REQ 005905	GSK-REQ 005908	1/1/1985	Journal of Medicinal Chemistry article "4-[2-(Di-n-propylamino)ethyl]-2(3H)-indolone: A Prejunctional Dopamine Receptor Agonist"	DX 30, PX 43
PTX 18	GSK-REQ 007942	GSK-REQ 007947	10/14/1985	Philadelphia Project Operating Committee Meeting Minutes	
PTX 19	GSK-REQ 014500	GSK-REQ 014504	11/8/1985	Philadelphia Project Operating Committee Meeting Minutes	
PTX 20	GSK-REQ 018136	GSK-REQ 018141	12/9/1985	Philadelphia R&D Project Operating Committee Meeting Minutes	DX 70

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 21	GSK-REQ 006741	GSK-REQ 006749	1/1/1986	Syntheses and in Vitro Evaluation of 4-(2-Aminoethyl)-2(3H)-indolones and Related Compounds as Peripheral Prejunctional Dopamine Receptor Agonists by DeMarinis, et al	DX 56, PX 54
PTX 22	GSK-REQ 014449	GSK-REQ 014457	1/9/1986	SK&F 101468 Project Team Meeting	DX 69
PTX 23	GSK-REQ 000208	GSK-REQ 000426	2/7/1986	Laboratory Notebook No. 3293/5573	DX 24
PTX 24	GSK-REQ 017394	GSK-REQ 017624	3/18/1986	Preliminary Investigation into the C.N.S. Penetration of SK&F 101468 and Related Material in the Conscious Rat	
PTX 25	GSK-REQ 014391	GSK-REQ 014406	7/16/1986	Minutes of the SK&F 101468-A Project Team Meeting Held on Wednesday, 16th July, 1986	DX 101 Exhibit is 14390-14406

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 26	GSK-REQ 001028	GSK-REQ 001071	7/16/1986	A Neuropharmacological Study, SK&F 101468-A: A Centrally Acting Dopamine Against Having Antiparkinson, Antidepressant and Anxiolytic Activity	DX 35
PTX 27	GSK-REQ 004891	GSK-REQ 004899	1/1/1987	Prejunctional Dopaminergic Activity of SK&F 101468-A in the Isolated Perfused Rabbit Ear Artery	
PTX 28	GSK-REQ 003935	GSK-REQ 003961	3/1/1987	The Effect of SK&F 101468-A on Blood Pressure and Heart Rate in the Conscious Spontaneously Hypertensive Rat	
PTX 29	GSK-REQ 013537	GSK-REQ 013543	4/6/1987	Minutes of the SK&F 101468-A Project Team Meeting	

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 30	GSK-REQ 020735	GSK-REQ020973	9/1/1987	SK&F 101468 Worldwide Development Plan and Review Document	DX 92
PTX 31	GSK-REQ 004067	GSK-REQ 004071	10/12/1987	Memo re: Critique of SK&F 101468 Project Review	DX 86
PTX 32	GSK-REQ136031	GSK-REQ136034	12/7/1987	Minutes of the SK&F 101468 WWCS Meeting held on 7th December, 1987	
PTX 33	GSK-REQ 007277	GSK-REQ 007284	3/3/1988	Minutes of SK&F 101468 Project Team Meeting Held on 3 March 1988	DX 89
PTX 34	GSK-REQ 008156	GSK-REQ 008169	3/16/1988	Minutes of Welwyn Project Operating Committee	
PTX 35	GSK-REQ 020566	GSK-REQ 020570	5/19/1988	U.S. Patent No. 4,824,860	PX 17, DX 48
PTX 36	GSK-REQ 019829	GSK-REQ 019834	5/19/1988	U.S. Patent No. 4,314,944	DX 47, 54

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 37	GSK-REQ 094434	GSK-REQ 094657	5/19/1988 - 04/25/1989	File History of U.S. Patent No. 4,824,860	
PTX 38	GSK-REQ 001371	GSK-REQ 001382	10/00/1988	Interaction of SK&F 101468-A and other DA-agonists with receptor binding sites	
PTX 39	GSK-REQ 004006	GSK-REQ 004040	3/1/1989	An Investigation into the Development of Tolerance to the Cardiovascular Effects of SK&F 101468-A in Cynomolgus Monkeys	
PTX 40	GSK-REQ 000074	GSK-REQ 000085	5/1/1989	The Effects of Chronic Administration of SK&F 101468-A in the MPTP-treated Common Marmoset (Callithrix jacchus)	DX 38
PTX 41	GSK-REQ 001195	GSK-REQ 001200	5/1/1989	Dopamine Agonist Action of SK7F 101468-A in Mouse Striatum Demonstrated after Unilateral 6-OHDA Lesions of the Substantia Nigra: Lack of Tolerance on Chronic Treatment	
PTX 42	GSK-REQ 004183	GSK-REQ 004260	5/1/1989	An Investigation into the Development of Tolerance to the Cardiovascular Effects of SK&F 101468-A in Spontaneously Hypertensive Rats	
PTX 43	GSK-REQ 013611	GSK-REQ 013618	7/23/1990	Article entitled, "Preclinical Pharmacology of Ropinirole (SK&F 101468-A) a Novel Dopamine D2 Agonist	DX 26
PTX 44	GSK-REQ 126009	GSK-REQ 126024	3/1/1994	The effect of ropinirole and its metabolites SK&F 89124, SK&F 104557, SKF 97930 and SK&F 96990 in the in vivo circling model of Parkinson's Disease.	
PTX 45	GSK-REQ 014656	GSK-REQ 014658	5/19/1998	Declaration and Power of Attorney	DX 97
PTX 46	GSK-JEN 001317	GSK-JEN 001323	5/24/2000	Article entitled, "Comparative Pharmacological Study of Ropinirole (SKF-101468) and its Metabolites in Rats, by Reavill, C.; Boyfield, I.; Coldwell, M. and Nelson, P., J. Pharm. Pharmacol. 2000, 52: 1129-1135 (2000).	
PTX 47	GSK-REQ 011473	GSK-REQ 014558	2/21/2005	Letter from Teva to Smith Kline re Patent Certification Notice - U.S. Patent Nos. 4,452,808 and 4,824,860	
PTX 48			5/5/2006	Gallagher's Hand Drawing comparing Ropinirole to 89124	DX 43
PTX 49			5/18/2006	Drawing Huffman made during his deposition of several compounds, including 89124	DX 55
PTX 50	GSK-REQ 013633	GSK-REQ 013634	unknown	Chemical Abstracts	

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 51	TEV-RQ 007302	TEV-RQ 007320	8/6/2001	Project Initiation Form	PX 1
PTX 52	TEV-RQ 000807	TEV-RQ 000813	12/22/2004	ANDA Table of Contents	PX 2
PTX 53	TEV-RQ 000827	TEV-RQ 000827	11/24/2004	Patent Certification (From Teva's ANDA)	PX 4
PTX 54			02/21/2005	Notification letter to GSK	PX 5
PTX 55	TEV-RQ 007323	TEV-RQ 007324	01/07/2003	Revised Trade Dress	PX 27
PTX 56	TEV-RQ 007193	TEV-RQ 007193		Teva chart describing ropinirole and noting minimal marketing in 2002	PX 23
PTX 57	GSK-REQ 024351	GSK-REQ 024354	9/11/1984	Biological Research Report No. 8400602	
PTX 58	GSK-REQ 011503	GSK-REQ 011503	7/26/1989	Certificate of name change (Smithkline Beecham Corporation to Smithkline Beecham Corporation)	
PTX 59			10/3/2005	Defendant Teva Pharmaceuticals U.S.A., Inc.'s Responses to Plaintiffs' First Set of Interrogatories and Defendant Teva Pharmaceuticals U.S.A., Inc.'s Responses to Plaintiff's First Set of Requests for Production of Documents and Tangible Things	
PTX 60			10/31/2005	Defendant Teva Pharmaceuticals U.S.A., Inc.'s Supplemental Responses to Plaintiffs' First Set of Interrogatories	
PTX 61			4/10/2006	Defendant Teva Pharmaceuticals U.S.A., Inc.'s Second Supplemental Responses to Plaintiffs' First Set of Interrogatories	PX 6
PTX 62			5/16/2006	Defendant Teva Pharmaceuticals U.S.A., Inc.'s Responses to Plaintiff GlaxoSmithKline's First Set of Requests for Admissions (Nos. 1-56)	
PTX 63			6/9/2006	Defendant Teva Pharmaceuticals U.S.A., Inc.'s Third Supplemental Responses to Plaintiff's First Set of Interrogatories	
PTX 64	TEV-RQ 000001	TEV-RQ 006053		Teva's ANDA	
PTX 65	TEV-RQ 000815	TEV-RQ 000819	12/22/2004	Application to Market a New Drug . . . For Human Use	PX 3
PTX 66	GSK-REQ 094245	GSK-REQ 094254		Requp P&L document	
PTX 67	GSK-REQ 136050	GSK-REQ 136059		Revised P&L document with 2006 information	
PTX 68	GSK-REQ 011486	GSK-REQ 011486		Assignment for '808 Patent	
PTX 69	GSK-REQ 014560	GSK-REQ 014560	5/19/1988	Assignment for '860 Patent	
PTX 70			4/11/2006	GSK's 30(b)(6) Notice of Deposition	PX 8
PTX 71	GSK-REQ 022444	GSK-REQ 022490	9/11/1989	¹⁴ C-SK&F 101468-A: Metabolism in the Rat and Cynomolgus Monkey	
PTX 72	GSK-REQ 094246A	GSK-REQ 94246A		Requp Brand P&L 1997-2005 (\$ in 000's)	DX 125
PTX 73			5/22/2006	Defendant's Teva Pharmaceuticals, U.S.A., Inc.'s Responses to Plaintiff's Second Set of Interrogatories and Defendant's Response to Plaintiff's Second Set of Requests for Production of Documents and Tangible Things	
PTX 74				University of Bradford Staff Profile: Brenda Costall (Pharmacy Dept)	DX 33
PTX 75				Drawings of Chemical Compounds including 89124	DX 55
PTX 76	GSK-REQ 018659	GSK-REQ 018699	6/5/1984	File History for U.S. Patent 4,452,808	
PTX 77	GSK-REQ 018613	GSK-REQ 018658	4/25/1989	File History for U.S. Patent 4,824,860	
PTX 78				REQUIP [®] Starter Kit	
PTX 79				Mirapex Starter Kit	
PTX 80	GSK-VEL 000249	GSK-VEL 000259	1948	Samuelson, P., "Consumption Theory in Terms of Revealed Preference," <i>Econometrica</i> , Vol. 15 (1948).	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 81			1968	Freiter ER, Cannon JG, Milne LD, Abood LG. Synthesis of compounds with potential psychotomimetic activity. <i>J Med Chem</i> 1968; 11(5):1041-1045.	
PTX 82			1972	Cannon JG, Smith RV, Modiri A, Sood SP, Borgman RJ, Aleem MA et al. Centrally acting emetics. 5. Preparation and pharmacology of 10-hydroxy-11 methoxyaporphine (isoapocodine). In vitro enzymatic methylation of apomorphine. <i>J Med Chem</i> 1972; 15(3):273-276.	
PTX 83			1974	Cannon JG, O'Donnell JP, Rosazza JP, Hoppen CR. Rigid amino acids related to alpha-methyl-dopa. <i>J Med Chem</i> 1974; 17(5):565-568.	
PTX 84	GSK-JEN 000052	GSK-JEN 000060	1975	Cannon JG. "Chemistry of dopaminergic agonists." <i>Adv. Neurol.</i> 9:177-83.; 177-183 (1975).	
PTX 85	GSK-JEN 000294	GSK-JEN 000300	1975	Clement-Cormier Y.C. et al., "Characterization of a dopamine-sensitive adenylate cyclase in the rat caudate nucleus." <i>J. Neurochem.</i> 25 (2): 143-149 (1975).	
PTX 86			1975	Ilhan M, Nichols DE, Long JP, Cannon JG. Apomorphine-like effect of an aminotetralin on the linguamandibular reflex of the cat. <i>Eur J Pharmacol</i> 1975; 33(1):61-64.	
PTX 87	GSK-JEN 000771	GSK-JEN 000779	1975	Iversen L. L., "Dopamine receptors in the brain." <i>Science</i> 188 (4193): 1084-1089 (1975).	
PTX 88	GSK-JEN 000308	GSK-JEN 000319	1976	Cools, A. R. and J. M. van Rossum, "Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of electrophysiological, biochemical, pharmacological, functional and clinical data." <i>Psychopharmacologia.</i> 45 (3): 243-254 (1976).	
PTX 89	GSK-JEN 000940	GSK-JEN 000950	1976	Nichols, D. E., "Structural Correlation between Apomorphine and LSD: Involvement of Dopamine as Well as Serotonin in the Actions of Hallucinogens." <i>J.Theor.Biol.</i> 59: 167-177 (1976).	
PTX 90			1976	Sharabi FM, Long JP, Cannon JG, Hatheway GJ. Inhibition of the sympathetic nervous system by a series of heterocyclic congeners of dopamine. <i>J Pharmacol Exp Ther</i> 1976; 199(3):630-638.	PX 39
PTX 91			1977	Costall B, Naylor RJ, Cannon JG, Lee T. Differential activation by some 2-aminotetralin derivatives of the receptor mechanisms in the nucleus accumbens of rats which mediate hyperactivity and stereotyped biting. <i>Eur J Pharmacol</i> 1977; 41(3):307-319.	PX 38
PTX 92	GSK-JEN 000521; GSK-BAR 000066; GSK-BAR 000077	GSK-JEN 000541; GSK-BAR 000076; GSK-BAR 000086	1977	Geissler, H. E., "3-(2-dipropylamino-ethyl)-phenol, a new, selective dopaminergic agonist," <i>Arch.Pharm.(Weinheim)</i> 310: 749-756 (1977).	PX 47
PTX 93	GSK-JEN 001189	GSK-JEN 001192	1977	Silbergeld, E. K. and R. F. Pfeiffer, "Differential effects of three dopamine agonists: apomorphine, bromocriptine and lepropride." <i>J Neurochem.</i> 28 (6): 1323-1326 (1977).	
PTX 94	GSK-JEN 001193	GSK-JEN 001196	1977	Silbergeld, E. K. et al., "The roles of presynaptic function and hepatic drug metabolism in the hypothermic actions of two novel dopaminergic agonists." <i>J Pharm.Pharmacol.</i> 29 (10): 632-635 (1977).	

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 95			1977	Volkman PH, Kohli JD, Goldberg LJ, Cannon JG, Lee T. Conformational requirements for dopamine-induced vasodilation. <i>Proc Natl Acad Sci U S A</i> 1977; 74(8):3602-3606.	
PTX 96	GSK-JEN 000061; TEV-RQEXP 000047; GSK-BAR 000142	GSK-JEN 000066; TEV-RQEXP 000052; GSK-BAR 000147	1978	Cannon JG, Hsu FL, Long JP, Flynn JR, Costall BJ, Naylor RJ. Preparation and biological actions of some symmetrically N,N-disubstituted dopamines. <i>J Med Chem</i> 1978; 21(3):248-253.	PX 53
PTX 97	GSK-JEN 000589	GSK-JEN 000597	1978	Goldberg, L. I. et al., "Characteristics of the vascular dopamine receptor: comparison with other receptors," <i>Fed Proc</i> , 37 (10): 2396-2402 (1978).	
PTX 98	GSK-JEN 000564	GSK-JEN 000588	1978	Goldberg, L. I., P. H. Volkman, and J. D. Kohli, "A comparison of the vascular dopamine receptor with other dopamine receptors," <i>Annu Rev Pharmacol Toxicol</i> , 18: 57-79 (1978).	
PTX 99			1978	Kitzen JM, Long JP, Cannon JG. Pharmacology of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99). I. Cardiovascular activity in the dog and cat. <i>J Pharmacol Exp Ther</i> 1978; 206(2):239-247.	
PTX 100	GSK-JEN 000854	GSK-JEN 000855	1978	Kornfeld, E. C. and Bach, N. J. Abstracts of Joint-Central Regional Great Lakes Region Meeting of the American Chemical Society, 107. 1978. Indianapolis, Indiana. 5-24-1978.	
PTX 101	GSK-JEN 000972	GSK-JEN 000976	1978	Parli, C. J., B. Schmidt, and C. J. Shaar, "Metabolism of lergotril to 13-hydroxy lergotril, a potent inhibitor of prolactin release in vitro," <i>Biochem Pharmacol</i> , 27 (9): 1405-1408 (1978).	
PTX 102	GSK-JEN 001298	GSK-JEN 001304	1978	Wong, D. T. and F. P. Bymaster, "An inhibitor of dopamine uptake, LR5182, cis-3-(3,4-dichlorophenyl)-2-n-n-dimethylaminomethyl-bicyclo-[2,2,2]-octan e, hydrochloride," <i>Life Sci</i> , 23 (10): 1041-1047 (1978).	
PTX 103	GSK-JEN 000552	GSK-JEN 000558	1979	Ginos, J. Z., J. M. Stevens, and D. E. Nichols, "Structure-activity relationships of n-substituted dopamine and 2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene analogues: behavioral effects in lesioned and reserpinized mice," <i>J Med Chem</i> , 22 (11): 1323-1329 (1979).	
PTX 104	GSK-JEN 000783	GSK-JEN 000786	1979	Jenner, P., C. D. Marsden, and C. Reavill, "Evidence for metabolic involvement in bromocriptine-induced circling behaviour [proceedings]," <i>Br J Pharmacol</i> , 66 (1): 103P-104P (1979).	
PTX 105	GSK-JEN 000798	GSK-JEN 000801	1979	Kebabian, J. W. and D. B. Calne, "Multiple receptors for dopamine," <i>Nature</i> , 277 (5692): 93-96 (1979).	
PTX 106	GSK-JEN 000873	GSK-JEN 000877	1979	Laduron, P. M. and J. E. Leysen, "Domperidone, a specific in vitro dopamine antagonist, devoid of in vivo central dopaminergic activity," <i>Biochem Pharmacol</i> , 28 (14): 2161-2165 (1979).	
PTX 107			1979	Rick J, Szabo M, Payne P, Kovathana N, Cannon JG, Frohman LA. Prolactin-suppressive effects of two aminotetralin analogs of dopamine: their use in the characterization of the pituitary dopamine receptor. <i>Endocrinology</i> 1979; 104(5):1234-1242.	
PTX 108	GSK-JEN 000010	GSK-JEN 000020	1980	Bach, N. J. et al., "Bicyclic and tricyclic ergoline partial structures. Rigid 3-(2-aminoethyl)pyrroles and 3- and 4-(2-aminoethyl)pyrazoles as dopamine agonists," <i>J Med Chem</i> , 23 (5): 481-491 (1980).	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 109	GSK-JEN 000320	GSK-JEN 000336	1980	Cools, A. R. and J. M. van Rossum. "Multiple receptors for brain dopamine in behavior regulation: concept of dopamine-E and dopamine-I receptors." <i>Life Sci.</i> 27 (14): 1237-1253 (1980).	
PTX 110	GSK-JEN 000734	GSK-JEN 000738	1980	Horn, A. S. and J. R. Rodgers. "2-amino-6,7-dihydroxytetrahydronaphthalene and the receptor-site preferred conformation of dopamine-a commentary." <i>J. Pharm. Pharmacol.</i> 32 (7): 521-524 (1980).	
PTX 111	GSK-JEN 000745	GSK-JEN 000748	1980	Horn, A. S. et al., "Synthesis and activity of the metabolite of a dopaminergic agonists 6,7-ADTN," <i>Eur. J. Med. Chem.</i> 15: 387-392 (1980).	
PTX 112	GSK-JEN 000981	GSK-JEN 000988	1980	Reavill, C., P. Jenner, and C. D. Marsden. "Metabolite involvement in bromocriptine-induced circling behaviour in rodents," <i>J. Pharm. Pharmacol.</i> 32 (4): 278-284 (1980).	
PTX 113	GSK-JEN 001089	GSK-JEN 001173	1980	Seeman, P., "Brain dopamine receptors," <i>Pharmacol. Rev.</i> 32 (3): 229-313 (1980).	
PTX 114	GSK-JEN 001209	GSK-JEN 001214	1980	Stoof, J. C., A. S. Horn, and A. H. Mulder. "Simultaneous demonstration of the activation of presynaptic dopamine autoreceptors and postsynaptic dopamine receptors in vitro by N,N-dipropyl-5,6-ADTN," <i>Brain Res.</i> 196 (1): 276-281 (1980).	
PTX 115	GSK-JEN 001253	GSK-JEN 001255	1980	Weinstock, J. et al., "Separation of potent central and renal dopamine agonist activity in substituted 6-chloro-2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepines," <i>J. Med. Chem.</i> 23 (9): 973-975 (1980).	
PTX 116	GSK-JEN 000067; GSK-BAR 000148	GSK-JEN 000071; GSK-BAR 000150	1981	Canon JG, Demopoulos BJ, Long JP, Flynn JR, Sharabi FM. Proposed dopaminergic pharmacophore of lergotril, pergolide, and related ergot alkaloid derivatives. <i>J Med Chem</i> 1981; 24(3):238-240.	DX 62, PX 45
PTX 117	GSK-JEN 000072; GSK-BAR 000001	GSK-JEN 000079; GSK-BAR 000006	1981	Canon JG, Long JP, Bhatnagar R. Future directions in dopaminergic nervous system and dopaminergic agonists. <i>J Med Chem</i> 1981; 24(10):1113-1118.	PX 51
PTX 118	GSK-JEN 000080	GSK-JEN 000084	1981	Canon, J. G. et al., "5,7-Dihydroxy-2-aminotetralin derivatives: synthesis and assessment of dopaminergic and adrenergic actions," <i>J. Med. Chem.</i> 24 (2): 149-153 (1981).	
PTX 119	GSK-JEN 000362	GSK-JEN 000369	1981	Creese, I. et al., "Dopamine receptors: subtypes, localization and regulation," <i>Fed. Proc.</i> 40 (2): 147-152 (1981).	
PTX 120	GSK-JEN 000692	GSK-JEN 000699	1981	Hackzell, U. et al., "3-Phenylpiperidines. Central dopamine-autoreceptor stimulating activity," <i>J. Med. Chem.</i> 24 (12): 1475-1482 (1981).	
PTX 121	GSK-JEN 000700; GSK-BAR 000170	GSK-JEN 000705; GSK-BAR 000175	1981	Hackzell, U. et al., "Monophenolic 2-(dipropylamino)indans and related compounds: central dopamine-receptor stimulating activity," <i>J. Med. Chem.</i> 24 (4): 429-434 (1981).	
PTX 122	GSK-JEN 000780	GSK-JEN 000782	1981	Jacob, J. N. et al., "Dopamine agonist properties of N-alkyl-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines," <i>J. Med. Chem.</i> 24 (8): 1013-1015 (1981).	
PTX 123			1981	Kotake C, Hoffmann PC, Goldberg LI, Cannon JG. Comparison of the effects of dopamine and beta-adrenergic agonists on adenylyl cyclase of renal glomeruli and striatum. <i>Mol Pharmacol</i> 1981; 20(2):429-434.	
PTX 124	GSK-JEN 001215	GSK-JEN 001218	1981	Stoof, J. C. and J. W. Kebabian. "Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat neostriatum." <i>Nature.</i> 294 (5839): 366-368 (1981).	
PTX 125	GSK-JEN 001235; GSK-BAR 000087	GSK-JEN 001243; GSK-BAR 000095	1981	Summers, C. et al., "Neurochemical and behavioural profiles of five dopamine analogues," <i>Naumyn Schmiedebergs Arch. Pharmacol.</i> 316 (4): 304-310 (1981).	PX 48

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 126	TEV-RQEXP 000005	TEV-RQEXP 000014	1982	Bhatnagar RK, Americ SP, Cannon JG, Flynn J, Long JP. Structure activity relationships of presynaptic dopamine receptor agonists. <i>Pharmacol Biochem Behav</i> 1982; 17(Suppl 1):11-19.	
PTX 127			1982	Cannon JG, Perez JA, Bhatnagar RK, Long JP, Sharabi FM. Conformationally restricted congeners of dopamine derived from 2-aminoindan. <i>J Med Chem</i> 1982; 25(12):1442-1446.	PX 52
PTX 128	GSK-JEN 000085	GSK-JEN 000099	1982	Cannon, J. G., J. P. Long, and B. J. Demopoulos, "Indole-derived Fragments of Ergot Alkaloids as Dopamine Congeners," <i>Adv. Biosci.</i> : 189-199 (1982).	PX 55
PTX 129	GSK-JEN 000181	GSK-JEN 000191	1982	Cavero, I., R. Massingham, and F. Lefevre-Borg, "Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part II: Sites and mechanisms of action of dopamine receptor agonists," <i>Life Sci.</i> 31 (11): 1059-1069 (1982).	
PTX 130	GSK-JEN 000148	GSK-JEN 000157	1982	Cavero, I., R. Massingham, and F. Lefevre-Borg, "Peripheral dopamine receptors, potential targets for a new class of antihypertensive agents. Part I: Subclassification and functional description," <i>Life Sci.</i> 31 (10): 939-948 (1982).	
PTX 131	GSK-JEN 000370	GSK-JEN 000377	1982	Cresce, I. and S. E. Leff, "Dopamine receptors: a classification," <i>J Clin Psychopharmacol.</i> 2 (5): 329-335 (1982).	
PTX 132	GSK-JEN 000378	GSK-JEN 000404	1982	Cresce, I. et al., "Dopamine receptors in the central nervous system," <i>Int. Rev. Neurobiol.</i> 23: 255-301 (1982).	
PTX 133	GSK-JEN 000686	GSK-JEN 000691	1982	Grosso, J. A. et al., "Synthesis of 2-(alkylamino)-5,6- and -6,7-dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists," <i>J Med Chem.</i> 25 (6): 703-708 (1982).	
PTX 134	GSK-JEN 000808	GSK-JEN 000821	1982	Kohli, J. D., D. Glock, and L. I. Goldberg, "Differential antagonism of postsynaptic (DA1) and presynaptic (DA2) peripheral dopamine receptors by substituted benzamides," <i>Adv Biochem Psychopharmacol.</i> 35: 97-108 (1982).	
PTX 135	GSK-JEN 000822	GSK-JEN 000828	1982	Kohli, J. D., L. I. Goldberg, and J. D. McDermid, "Modification of cardiovascular actions of 2-amino-5,6-dihydroxytetralin by N,N-di-n-propyl substitution," <i>Eur. J Pharmacol.</i> 81 (2): 293-299 (1982).	
PTX 136	GSK-JEN 000878	GSK-JEN 000885	1982	Lang, W. J. and O. L. Woodman, "Comparison of the vasodilator action of dopamine and dopamine agonists in the renal and coronary beds of the dog," <i>Br. J Pharmacol.</i> 77 (1): 23-28 (1982).	
PTX 137	GSK-JEN 000894	GSK-JEN 000905	1982	List, S. J., K. A. Wreggett, and P. Seeman, "Sirtal binding of 2-amino-6,7-[3H]dihydroxy-1,2,3,4-tetrahydronaphthalene to two dopaminergic sites distinguished by their low and high affinity for neuroleptics," <i>J Neurosci.</i> 2 (7): 895-906 (1982).	
PTX 138	GSK-JEN 000931	GSK-JEN 000933	1982	Neumeyer, J. L. et al., "Aporphines. 39. Synthesis, dopamine receptor binding, and pharmacological activity of (R)-(-) and (S)-(+)-2-hydroxyapomorphine," <i>J Med Chem.</i> 25 (8): 990-992 (1982).	
PTX 139	GSK-JEN 001024	GSK-JEN 001033	1982	Schmidt, M. et al., "Vasodilator effects of dopaminomimetics in the perfused rat kidney," <i>Eur. J Pharmacol.</i> 84 (1-2): 61-70 (1982).	PX 49
PTX 140	GSK-JEN 001174	GSK-JEN 001179	1982	Seeman, P., "Nomenclature of central and peripheral dopaminergic sites and receptors," <i>Biochem. Pharmacol.</i> 31 (16): 2563-2569 (1982).	
PTX 141	GSK-JEN 001291	GSK-JEN 001297	1982	Wikstrom, H. et al., "Monophenolic octahydrobenzo[<i>f</i>]quinolines: central dopamine- and serotonin-receptor stimulating activity," <i>J Med Chem.</i> 25 (8): 925-931 (1982).	
PTX 142	GSK-VEL 000202	GSK-VEL 000203	1/1/1982	Orange Book Detail Record Search: Carbidopa: Levodopa "017555"	
PTX 143	GSK-BER 000567	GSK-BER 000571	Sep-82	MPEP § 608.01(p) (4th ed., rev. Sep. 1982)	
PTX 144			1983	Cannon JG, Patrick KS, Long JP, Ilhan M. Semi-rigid ketone congeners of catecholamines. <i>Eur J Med Chem Chim Ther</i> 1983; 18(3):291-292.	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 145	GSK-BAR 000026	GSK-BAR 000055	1983	Cannon JG. Structure-activity relationships of dopamine agonists. <i>Annu Rev Pharmacol Toxicol</i> 1983; 23:103-129.	
PTX 146	GSK-JEN 000127	GSK-JEN 000133	1983	Carlsson, A., "Dopamine receptor agonists: intrinsic activity vs. state of receptor." <i>J Neural Transm</i> . 57 (4): 309-315 (1983).	
PTX 147	GSK-JEN 000435	GSK-JEN 000446	1983	Creese, I. et al., "Dopamine receptors in the central nervous system." <i>Adv Biochem Psychopharmacol</i> . 36: 125-134 (1983).	
PTX 148	GSK-JEN 000405	GSK-JEN 000434	1983	Creese, I. et al., "The classification of dopamine receptors: relationship to radioligand binding." <i>Annu Rev Neurosci</i> . 6: 43-71 (1983).	
PTX 149	GSK-JEN 000447	GSK-JEN 000460	1983	Creese, I., D. R. Sibley, and S. Leff, "Classification of dopamine receptors." <i>Adv Biochem Psychopharmacol</i> . 37: 255-266 (1983).	
PTX 150	GSK-JEN 000542	GSK-JEN 000551	1983	George, S., K. Binkley, and P. Seeman, "Dopamine receptor sites and states in human brain." <i>J Neural Transm Suppl</i> . 18: 149-156 (1983).	
PTX 151	GSK-JEN 000836	GSK-JEN 000841	1983	Kohli, J. D., D. Glock, and L. I. Goldberg, "Effects of the enantiomers of 3-PPP on DA1 and DA2 dopamine receptors in the dog." <i>Eur J Pharmacol</i> . 114 (3): 305-310 (1985).	
PTX 152	GSK-JEN 000934	GSK-JEN 000939	1983	Neumeyer, J. L. et al., "Aporphines. 48. Enantioselectivity of (R)-(-) and (S)-(+)-N-n-propylthoraporphine on dopamine receptors." <i>J Med Chem</i> . 26 (4): 516-521 (1983).	
PTX 153	GSK-JEN 000989	GSK-JEN 000994	1983	Reavill, C., P. Jenner, and C. D. Marsden, "Differentiation of dopamine agonists using drug-induced rotation in rats with unilateral or bilateral 6-hydroxydopamine destruction of ascending dopamine pathways." <i>Biochem Pharmacol</i> . 32 (5): 865-870 (1983).	
PTX 154	GSK-BER 000096	GSK-BER 000121	1983	Irving Kayton, Kayton on Patents, 2nd ed., 3-1, 1983	
PTX 155	GSK-JEN 000028	GSK-JEN 000044	1984	Bradbury, A. J. et al., "A comparison of dopamine agonist action to inhibit locomotor activity and to induce stereotyped behaviour in the mouse." <i>Eur J Pharmacol</i> . 105 (1-2): 33-47 (1984).	
PTX 156	GSK-JEN 000100; TEV. ROEXP 000053; GSK-BAR 000122	GSK-JEN 000105; TEV. ROEXP 000056; GSK-BAR 000125	1984	Cannon JG, Lee T, Ithan M, Koons J, Long JP. 6-Hydroxy-4-[2-(di-n-propylaminoethyl)indole: synthesis and dopaminergic actions. <i>J Med Chem</i> 1984; 27(3):386-389.	
PTX 157	GSK-JEN 000286	GSK-JEN 000293	1984	Clemens, J. A. et al., "Stimulation of presynaptic dopamine autoreceptors by 4-(2-di-n-propylaminoethyl) indole (DPAI)." <i>Life Sci</i> . 34 (11): 1015-1022 (1984).	
PTX 158	GSK-JEN 000337	GSK-JEN 000354	1984	Cools, A. R., "Basal ganglia and Parkinson's disease: neurobiological and pharmacological aspects in animals and man." <i>Clin Neuropharmacol</i> . 86 (3): 178-195 (1984).	
PTX 159	GSK-JEN 000461	GSK-JEN 000467	1984	Creese, I., D. R. Sibley, and S. E. Leff, "Agonist interactions with dopamine receptors: focus on radioligand-binding studies." <i>Fed Proc</i> . 43 (13): 2779-2784 (1984).	

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 160	GSK-JEN 000598	GSK-JEN 000605	1984	Goldberg, L. I. et al., "Separation of peripheral dopamine receptors by a selective DA1 antagonist, SCH 23390," <i>Hypertension</i> 6 (2 Pt 2): 125-130 (1984).	
PTX 161	GSK-JEN 000606	GSK-JEN 000615	1984	Goldberg, L. I., "Dopamine receptors and hypertension. Physiologic and pharmacologic implications," <i>Am.J.Med.</i> 77 (4A): 37-44 (1984).	
PTX 162	GSK-JEN 000680	GSK-JEN 000685	1984	Groisman, S. D., T. G. Karevina, and V. P. Khokholia, "Role of dopamine receptors in the mechanism of formation of stress-induced stomach lesions," <i>Bull. Eksp. Biol. Med.</i> 97 (1): 57-60 (1984).	
PTX 163			1984	Ilhan M, Long JP, Bhatnagar R, Flynn J, Cannon JG, Lee T. TL-350, an ergoline derivative with dopamine receptor agonist properties. <i>J Pharmacol Exp Ther</i> 1984; 231(1):56-60.	
PTX 164	GSK-JEN 000802	GSK-JEN 000807	1984	Kebabian, J. W., M. Beaulieu, and Y. Itoh, "Pharmacological and biochemical evidence for the existence of two categories of dopamine receptor," <i>Can.J.Neurol.Sci.</i> 11 (1 Suppl): 114-117 (1984).	
PTX 165			1984	Koons JC, Long JP, Cannon JG. In vivo and in vitro dopaminergic effects of three ergoline fragments. <i>Naunyn Schmiedeberg Arch Pharmacol</i> 1984; 328(2):180-185.	
PTX 166	GSK-JEN 000906	GSK-JEN 000912	1984	Lokhandwala, M. F. and M. L. Steenberg, "Evaluation of the effects of SKF 82526 and LY 171555 on presynaptic (DA2) and postsynaptic (DA1) dopamine receptors in rat kidney," <i>J Auton Pharmacol.</i> 4 (4): 273-277 (1984).	
PTX 167	GSK-JEN 001075	GSK-JEN 001088	1984	Schwartz, J. C. et al., "Multiple dopamine receptors: the D3 receptor and actions of substances of abuse," <i>EXS</i> 71: 81-92 (1994).	
PTX 168	GSK-JEN 001048	GSK-JEN 001061	1984	Schwartz, J., "The dopaminergic system in the periphery," <i>J Pharmacol.</i> 15 (4): 401-414 (1984).	
PTX 169	GSK-JEN 001219	GSK-JEN 001234	1984	Stoof, J. C. and J. W. Kebabian, "Two dopamine receptors: biochemistry, physiology and pharmacology," <i>Life Sci.</i> 35 (23): 2281-2296 (1984).	
PTX 170	GSK-JEN 001244	GSK-JEN 001252	1984	Wachtel, H., R. Derow, and G. Sauer, "Novel 8 alpha-ergolines with inhibitory and stimulatory effects on prolactin secretion in rats," <i>Life Sci.</i> 35 (18): 1859-1867 (1984).	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 171	TEV-RQEXP 000358	TEV-RQEXP 000469	1985	Cannon JG. Dopamine agonists: structure-activity relationships. <i>Prog Drug Res</i> 1985; 29:303-414.	PX 58
PTX 172	GSK-JEN 000192	GSK-JEN 000243	1985	Clark, D., S. Hjorth, and A. Carlsson. "Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence." <i>J Neural Transm</i> . 62 (1-2): 1-52 (1985).	
PTX 173	GSK-JEN 000244	GSK-JEN 000280	1985	Clark, D., S. Hjorth, and A. Carlsson. "Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations." <i>J Neural Transm</i> . 62 (3-4): 171-207 (1985).	
PTX 174	GSK-JEN 000281	GSK-JEN 000285	1985	Clark, D., S. Hjorth, and A. Carlsson. "(-)- and (-)-3-PPP exhibit different intrinsic activity at striatal dopamine autoreceptors controlling dopamine synthesis." <i>Eur J Pharmacol</i> . 106 (1): 185-189 (1985).	
PTX 175	GSK-JEN 000305	GSK-JEN 000307	1985	Close, S. P., A. S. Marriott, and S. Pay. "Failure of SKF 38393-A to relieve parkinsonian symptoms induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the marmoset." <i>Br J Pharmacol</i> . 85 (2): 320-322 (1985).	
PTX 176	GSK-JEN 000510	GSK-JEN 000514	1985	Frederickson, E. D., T. Bradley, and L. I. Goldberg. "Blockade of renal effects of dopamine in the dog by the DA1 antagonist SCH 23390." <i>Am J Physiol</i> 249 (2 Pt 2): F236-F240 (1985).	
PTX 177	GSK-JEN 000739	GSK-JEN 000744	1985	Horn, A. S. et al., "Synthesis and radioreceptor binding activity of N-0437, a new, extremely potent and selective D2 dopamine receptor agonist." <i>Pharm. Weekbl Sci</i> . 7 (5): 208-211 (1985).	
PTX 178	GSK-JEN 000856	GSK-JEN 000864	1985	Krejci, I. et al., "Lisuride and transdihydrolisuride: differences in action on central dopaminergic functions in dependence on the location and the state of receptors." <i>Pol J Pharmacol Pharm</i> . 37 (3): 263-271 (1985).	
PTX 179	GSK-JEN 000967	GSK-JEN 000971	1985	Nomoto, M., P. Jenner, and C. D. Marsden. "The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset." <i>Neurosci Lett</i> . 57 (1): 37-41 (1985).	
PTX 180	GSK-JEN 001180	GSK-JEN 001188	1985	Seeman, P. et al., "Dopamine D2 receptor binding sites for agonists. A tetrahedral model." <i>Mol Pharmacol</i> . 28 (5): 391-399 (1985).	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 181	GSK-JEN 000106; TEV-ROEXP 000249; GSK-REQ 020655; GSK-BAR 000126	GSK-JEN 000112; TEV-ROEXP 000254; GSK-REQ 020660; GSK-BAR 000132	1986	Cannon JG. The Design of Potential Anti-Parkinsonian Drugs: What is the Dopaminergic Pharmacophore in Ergot Alkaloids? <i>Proc. Iona Acad Sci</i> 1986; 93:169-174.	PX 44
PTX 182	GSK-JEN 000134	GSK-JEN 000139	1986	Carlsson, A., "Development of new pharmacological approaches in Parkinson's disease," <i>Adv. Neurol.</i> 45: 513-518 (1986).	
PTX 183	GSK-JEN 000829	GSK-JEN 000835	1986	Kohli, J. D. D. Glock, and L. I. Goldberg, "Selective DA2 versus DA1 antagonist activity of domperidone in the periphery," <i>Eur. J. Pharmacol.</i> 89 (1-2): 137-141 (1983).	
PTX 184	GSK-JEN 000865	GSK-JEN 000872	1986	Ladd, D. L. et al., "Synthesis and dopaminergic binding of 2-aryl(dopamine analogues: phenethylamines, 3-benzazepines, and 9-(aminomethyl)fluorenes," <i>J. Med. Chem.</i> 29 (10): 1904-1912 (1986).	
PTX 185	GSK-JEN 000913	GSK-JEN 000921	1986	Lombardi, D. M. et al., "DA ₁ receptor mediates dopamine-induced relaxation of opossum lower esophageal sphincter in vitro," <i>Gastroenterology</i> 91 (3): 533-539 (1986).	
PTX 186	GSK-JEN 001000	GSK-JEN 001007	1986	Ross, S. T. et al., "Dopamine receptor agonists: 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol and a series of related 3-benzazepines," <i>J. Med. Chem.</i> 29 (5): 733-740 (1986).	
PTX 187	GSK-JEN 001256	GSK-JEN 001268	1986	Weinstock, J. et al., "Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins," <i>J. Med. Chem.</i> 29 (9): 1615-1627 (1986).	
PTX 188	GSK-JEN 001269	GSK-JEN 001279	1986	Weinstock, J. et al., "Synthesis and renal vasodilator activity of some dopamine agonist 1-aryl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diols: halogen and methyl analogues of fenoldopam," <i>J. Med. Chem.</i> 29 (11): 2315-2325 (1986).	
PTX 189	GSK-SUD 000016	GSK-SUD 000017	1986	Cooper, JR., Bloom FE, Roth RH. The Biochemical Basis of Neuropharmacology. 5th ed. New York, NY: Oxford University Press, 1986.	
PTX 190	GSK-JEN 000021	GSK-JEN 000027	1987	Beart, P. M. et al., "Radioreceptor binding reveals the potencies of N,N-disubstituted 2-aminotetralins as D2 dopamine agonists," <i>Nature Schmiedeleberg's Arch. Pharmacol.</i> 336 (5): 487-493 (1987).	
PTX 191	GSK-JEN 000143	GSK-JEN 000147	1987	Carlsson, M., A. Carlsson, and E. Eriksson, "The intrinsic activities of the partial dopamine receptor agonists (-)-3-PPP and TDHL on pituitary dopamine receptors are lower in female than in male rats," <i>Eur. J. Pharmacol.</i> 142 (1): 39-43 (1987).	
PTX 192	GSK-JEN 000483	GSK-JEN 000487	1987	Dumbrille-Ross, A. and P. Seeman, "Dopamine agonist high-affinity state in solubilized D2 receptors in striatum, but not in anterior pituitary," <i>Biochem. Pharmacol.</i> 36 (13): 2095-2099 (1987).	
PTX 193	GSK-JEN 000616	GSK-JEN 000620	1987	Goldberg, L. I. and J. D. Kohli, "Identification and characterization of dopamine receptors in the cardiovascular system," <i>Cardiologia</i> 32 (12): 1603-1607 (1987).	

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 194	GSK-JEN 000621	GSK-JEN 000635	1987	Goldberg, L. I. and M. B. Murphy, "Potential use of DA1 and DA2 receptor agonists in the treatment of hypertension," <i>Clin. Exp. Hypertens. A</i> 9 (5-6): 1023-1035 (1987).	
PTX 195	GSK-JEN 000712	GSK-JEN 000733	1987	Hilditch, A. and G. M. Drew, "Subclassification of peripheral dopamine receptors," <i>Clin. Exp. Hypertens. A</i> 9 (5-6): 853-872 (1987).	
PTX 196	GSK-JEN 000787	GSK-JEN 000797	1987	Johansson, A. M. et al., "C1- and C3-methyl-substituted derivatives of 7-hydroxy-2-(di-n-propylamino)tetralin: activities at central dopamine receptors," <i>J. Med. Chem.</i> 30 (10): 1827-1837 (1987).	
PTX 197	GSK-JEN 000922	GSK-JEN 000930	1987	Martinez-Mir, I., F. J. Morales-Olivas, and E. Rubio, "The lack of the effect of DA-1 and DA-2 dopamine agonists on the isolated guinea-pig atria," <i>J. Auton. Pharmacol.</i> 7 (2): 111-117 (1987).	
PTX 198	GSK-JEN 000995	GSK-JEN 000999	1987	Riggs, R. M. et al., "Specific dopamine D-1 and DA1 properties of 4-mono- and -dihydroxyphenyl-1,2,3,4-tetrahydroisoquinoline and its tetrahydrothieno[2,3-c]pyridine analogue," <i>J. Med. Chem.</i> 30 (8): 1454-1458 (1987).	
PTX 199	GSK-JEN 001008	GSK-JEN 001013	1987	Ross, S. T. et al., "Dopamine agonists related to 3-allyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol, 6-Position modifications," <i>J. Med. Chem.</i> 30 (1): 35-40 (1987).	
PTX 200	GSK-JEN 001280	GSK-JEN 001290	1987	Weinstock, J. et al., "Synthesis and evaluation of non-catechol D-1 and D-2 dopamine receptor agonists: benzimidazol-2-one, benzoxazol-2-one, and the highly potent benzothiazol-2-one 7-ethylamines," <i>J. Med. Chem.</i> 30 (7): 1166-1176 (1987).	
PTX 201	GSK-BER 000007	GSK-BER 000019	07/21/1987	U.S. Patent No. 5,585,358	
PTX 202	GSK-JEN 000001	GSK-JEN 000009	1988	Allen, M. J., V. T. Ang, and E. D. Bennett, "Domperidone, a DA2-specific dopamine antagonist, has no effect on the renal or haemodynamic response to atrial natriuretic peptide in man," <i>Clin. Sci. (Lond.)</i> 75 (6): 569-575 (1988).	
PTX 203	GSK-JEN 000113	GSK-JEN 000120	1988	Cannon JG. Dopaminergic Agonists: The Status Quo and the Future. In: Beart PM, Woodruff GN, Jackson DM, editors. Pharmacology and Functional Regulation of Dopaminergic Neurons. London: Macmillan Press; 1988. p. 1-8.	
PTX 204	GSK-JEN 000497	GSK-JEN 000509	1988	Foucart, S. et al., "Modulation of adrenal catecholamine release by DA2 dopamine receptors in the anaesthetized dog," <i>Clin. Exp. Pharmacol. Physiol.</i> 15 (8): 601-611 (1988).	
PTX 205	GSK-JEN 000654	GSK-JEN 000664	1988	Goldberg, L. I., "Dopamine and new dopamine analogs: receptors and clinical applications," <i>J. Clin. Anesth.</i> 1 (1): 66-74 (1988).	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 206	GSK-JEN 000636	GSK-JEN 000653	1988	Goldberg, L. I., J. D. Kohli, and D. Glock. 1988. Conclusive Evidence for Two Subtypes of Dopamine Receptors. In <i>Pharmacology and Functional Regulation of Dopaminergic Neurons</i> . Edited by P. M. Beart, G. N. Woodruff, and D. M. Jackson. London: Macmillan Press.	
PTX 207	GSK-JEN 000706	GSK-JEN 000711	1988	Hietala, J. "Effects of DA-1- and DA-2-dopamine antagonists on apomorphine-induced inhibition of peripheral sympathetic neurotransmission." <i>J. Auton. Pharmacol.</i> 8 (4): 297-302 (1988).	
PTX 208	GSK-JEN 001309	GSK-JEN 001316	1988	Mannelli, M. et al. "Endogenous dopamine (DA) and DA2 receptors: a mechanism limiting excessive sympathetic-adrenal discharge in humans." <i>J. Clin. Endocrinol. Metab.</i> 66 (3): 626-631 (1988).	
PTX 209	GSK-JEN 001034	GSK-JEN 001047	1988	Schmidt, M., J. L. Imbs, and J. Schwartz. 1988. Pharmacological Characterization of the Dopamine Renal Vascular Receptor. In <i>Pharmacology and Functional Regulation of Dopaminergic Neurons</i> . Edited by P. M. Beart, G. N. Woodruff, and D. M. Jackson. London: Macmillan Press.	
PTX 210	GSK-JEN 000476	GSK-JEN 000482	1989	Dilewaj, A., H. O. Watkins, and M. F. Lokhandwala. "Effects of SK&F 85174, a DA-1/DA-2 receptor agonist, on pre- and postganglionic sympathetic neurotransmission to the heart." <i>Eur. J. Pharmacol.</i> 164 (2): 197-203 (1989).	
PTX 211	GSK-JEN 000488	GSK-JEN 000496	1989	Foreman, M. M. et al. "Preclinical studies on quinlorane, a potent and highly selective D2-dopaminergic agonist." <i>J. Pharmacol. Exp. Ther.</i> 250 (1): 227-235 (1989).	
PTX 212	GSK-JEN 000559	GSK-JEN 000563	1989	Glavin, G. B. "Activity of selective dopamine DA1 and DA2 agonists and antagonists on experimental gastric lesions and gastric acid secretion." <i>J. Pharmacol. Exp. Ther.</i> 251 (2): 726-730 (1989).	
PTX 213	GSK-JEN 000842	GSK-JEN 000849	1989	Kohli, J. D. et al. "Dopamine receptors in the stellate ganglion of the dog." <i>Eur. J. Pharmacol.</i> 164 (2): 265-272 (1989).	
PTX 214	GSK-JEN 000951	GSK-JEN 000957	1989	Nichols, D. E. et al. "Synthesis and evaluation of N,N-di-n-propyltetrahydrobenzof[7]indol-7-amine and related congeners as dopaminergic agonists." <i>J. Med. Chem.</i> 32 (9): 2128-2134 (1989).	
PTX 215	GSK-JEN 000977	GSK-JEN 000980	1989	Ramsby, S. et al. "2-Haloaporphines as potent dopamine agonists." <i>J. Med. Chem.</i> 32 (6): 1198-1201 (1989).	
PTX 216	GSK-VEL 000180	GSK-VEL 000180	12/12/1989	Mirapex ® Patent Term Extension Certificate	
PTX 217	GSK-JEN 000045	GSK-JEN 000051	1990	Brodde, O. E. "Subclassification of peripheral dopamine receptors." <i>J. Auton. Pharmacol.</i> 10 Suppl 1: s5-s9 (1990).	
PTX 218			1990	Cannon JG, Walker KA, Montanari A, Long JP, Flynn J. Monomethyl ether derivatives of 7,8-dihydroxy- and 8,9-dihydroxy-4-n-propyl-1,2,3,4,4a,5,6,10b-octahydrobenzo[f]quinolines as possible products of metabolism by catechol-O-methyltransferase. <i>J. Med. Chem.</i> 33(7):2000-2006.	
PTX 219	GSK-VEL 000181	GSK-VEL 000195	1990	Scherer, F.M. and Ross, D., <i>Industrial Market Structure and Economic Performance</i> , Boston: Houghton Mifflin, 1990: 582-592.	
PTX 220	GSK-JEN 000355	GSK-JEN 000361	1990	Coward, D. M. et al. "Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912." <i>J. Pharmacol. Exp. Ther.</i> 252 (1): 279-285 (1990).	
PTX 221	GSK-JEN 000468	GSK-JEN 000475	1990	Damase-Michel, C. et al. "Effect of quiprole, a specific dopamine DA2 receptor agonist on the sympathoadrenal system in dogs." <i>J. Pharmacol. Exp. Ther.</i> 252 (2): 770-777 (1990).	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 222	GSK-JEN 000515	GSK-JEN 000520	1990	Gao, Y. G. et al., "Synthesis and structural requirements of N-substituted norapomorphines for affinity and activity at dopamine D-1, D-2, and agonist receptor sites in rat brain," <i>J. Med. Chem.</i> 33 (1): 39-44 (1990).	
PTX 223	GSK-JEN 000850	GSK-JEN 000853	1990	Kohli, J. D., "Peripheral dopamine receptors," <i>Am. J. Hypertens.</i> 3 (6 Pt 2): 25S-28S (1990).	
PTX 224	GSK-JEN 000886	GSK-JEN 000893	1990	Liljeblom, T. et al., "Pre- and postsynaptic dopaminergic activities of indolizidine and quinolizidine derivatives of 3-(3-hydroxyphenyl)-N-(n-propyl)pyrrolidine (3-PPP). Further developments of a dopamine receptor model," <i>J. Med. Chem.</i> 33 (3): 1015-1022 (1990).	
PTX 225	GSK-JEN 000755	GSK-JEN 000760	1991	Horn, P. T. and J. D. Kohli, "Absence of postsynaptic DA2 dopamine receptors in the dog renal vasculature," <i>Eur. J. Pharmacol.</i> 197 (2-3): 125-130 (1991).	
PTX 226	GSK-JEN 000761	GSK-JEN 000765	1991	Huo, T., M. Q. Ye, and D. P. Healy, "Characterization of a dopamine receptor (DA2K) in the kidney inner medulla," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 88 (8): 3170-3174 (1991).	
PTX 227	GSK-JEN 000958	GSK-JEN 000966	1991	Nishiyama, S., M. Yoshikawa, and I. Yamaguchi, "A novel orally active dopamine (DA) produg TA-870. IV. Renal vasodilatory and negative chronotropic effects in anesthetized dogs: influence of DA1 and DA2 dopamine receptor selective antagonists," <i>J. Cardiovasc. Pharmacol.</i> 17 (4): 560-567 (1991).	
PTX 228	GSK-JEN 000121	GSK-JEN 000126	1992	Cannon J.G., Roufos I, Ma SX, Long JP. Derivatives of 4-(2-N,N-di-n-propylaminoethyl)-5-hydroxyindole: synthesis and pharmacological effects. <i>Pharm Res</i> 1992; 9(6):735-738.	
PTX 229			1992	Cannon, J. G. et al., "Derivatives of 4-(2-N,N-di-n-propylaminoethyl)-5-hydroxyindole: synthesis and pharmacological effects," <i>Pharm. Res.</i> 9 (6): 735-738 (1992).	
PTX 230	GSK-JEN 000140	GSK-JEN 000142	1992	Carlsson, A., "Fifteen years of continued research in psychopharmacology," <i>Pharmacopsychiatry</i> 25 (1): 22-24 (1992).	
PTX 231			1993	Cannon J.G., Kirschbaum KS, Annoo VE, Johnson AK, Long JP. 2,5-Dimethoxy congeners of (+)- and (-)-3-(3-hydroxyphenyl)-N-n-propylpyrrolidine. <i>J Med Chem</i> 1993; 36(16):2416-2419.	
PTX 232	GSK-JEN 001014	GSK-JEN 001023	1993	Rump, L. C. et al., "Dopamine DA2-receptor activation inhibits noradrenaline release in human kidney slices," <i>Kidney Int.</i> 43 (1): 197-204 (1993).	
PTX 233			1995	Cannon J.G., Analog Design. In: Wolff ME, editor. Burger's medicinal Chemistry and Drug Discovery. Fifth ed. 1995. p. 783-802.	
PTX 234			1995	Jenner, P., "The rationale for the use of dopamine agonists in Parkinson's disease," <i>Neurology</i> 45 (3, Supplement 3): S6-12 (1995).	
PTX 235	GSK-JEN 001203	GSK-JEN 001208	1995	Sokoloff, P. and J. C. Schwartz, "Novel dopamine receptors half a decade later," <i>Trends Pharmacol. Sci.</i> 16 (8): 270-275 (1995).	
PTX 236	GSK-JEN 001197	GSK-JEN 001202	1996	Snyder, S. H. 1996. <i>Drugs and the Brain</i> . Vol. 18.	
PTX 237	GSK-VEL 000238	GSK-VEL 000241	4/22/1996	FDA Center for Drug Evaluation and Research Manual of Policies and Procedures: Priority Review Policy	
PTX 238	GSK-BER 000020	GSK-BER 000030	12/17/1996	U.S. Patent No. 4,681,893	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 239	GSK-VEL 000154	GSK-VEL 000179	Jul-97	Drug Approvals for July 1997	
PTX 240	GSK-VEL 000001	GSK-VEL 000023	Sep-97	Drug Approvals for September 1997	
PTX 241	GSK-JEN 000301	GSK-JEN 000304	1998	Clementi, G. et al., "Involvement of DA1 and DA2 receptors in the gastroprotective activity of amylin in the rat," <i>Pharmacol. Res.</i> 38 (3): 221-224 (1998).	
PTX 242			1998	Pearce, R. K. et al., "De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset," <i>Movement Disorders: Official Journal Of The Movement Disorder Society</i> 13 (2): 234-241 (1998).	
PTX 243	GSK-JEN 001062	GSK-JEN 001072	1998	Schwartz, J. Dopamine Receptors in the IUPHAR Compendium of Receptor Characterization and Classification. Girdlestone, D. 141-151. 1998. London, IUPHAR Media.	
PTX 244	GSK-SUD 000055	GSK-SUD 000060	10/00/1998	Lieberman A, Olanow CW, Sethi K, Swanson, P, Waters, CH, Fahm, S, Hurtig, H, Yahr, M. A multicenter trial of ropinirole as adjunct treatment for Parkinson's Disease. <i>Neurology</i> 1998; 51:1057-62.	
PTX 245	GSK-SUD 000031	GSK-SUD 000040	10/08/1998	Lang AE, Lozano AM. Parkinson's Disease: First of Two Parts. <i>N Engl J Med</i> 1998; 339:1044-1053.	
PTX 246	GSK-SUD 000041	GSK-SUD 000054	10/15/1998	Lang AE, Lozano AM. Parkinson's Disease: Second of Two Parts. <i>N Engl J Med</i> 1998; 339:1130-1143.	
PTX 247	GSK-VEL 000149	GSK-VEL 000151	10/19/1998	Mirapex®/Sifrol® (pramipexole) study shows improvement in tremor among patients with Parkinson's Disease	
PTX 248	GSK-SUD 000008	GSK-SUD 000015	1999	Chesson AL, Wise M, Davila D, Johnson S, Littner M, Anderson WM, Hartse K, Rafecas J. Practice parameters for the treatment of restless legs syndrome and periodic limb movement disorder. An American Academy of Sleep Medicine Report. Standards of Practice Committee of the American Academy of Sleep Medicine. <i>Sleep</i> 1999; 22(7):961-68.	
PTX 249	GSK-VEL 000147	GSK-VEL 000148	7/26/1999	Friend, Tim. "Better drugs to treat tremors"; <i>USA Today</i> (USA), July 26, 1999	
PTX 250	GSK-VEL 000232	GSK-VEL 000233	10/19/1999	FDA Consumer Drug and Information Sheet: Comtan	
PTX 251	GSK-JEN 001305	GSK-JEN 001308	2000	Zhang, W. F. et al., "Effects of tetrahydroberberine on peripheral vascular dopamine DA1 and DA2 receptor subtypes," <i>Zhongguo Zhong Yao Za Zhi</i> , 25 (8): 497-500 (2000).	
PTX 252	GSK-REQ 089278	GSK-REQ 089294	2000	Advertisement including NEJM article	
PTX 253	GSK-REQ 092494	GSK-REQ 092513	2000	NEJM article: advertisement; and Requip product label	
PTX 254	GSK-VEL 000214	GSK-VEL 000231	Mar-00	Comtan Prescribing Information	
PTX 255	GSK-SUD 000118, GSK-REQ092494	GSK-SUD 000125; GSK-REQ092513	05/18/2000	Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke, CE, Lang, AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's Disease who were treated with ropinirole or levodopa. <i>N Engl J Med</i> 2000; 342:1484-91.	
PTX 256	GSK-VEL 000141	GSK-VEL 000146	5/22/2000	Cowly, Geoffrey. "The New War on Parkinson's"; <i>Newsweek</i> , May 22, 2000: Newsweek, Inc. U.S. Edition, p. 52.	
PTX 257	GSK-REQ058447	GSK-REQ058571	06/29/2000	Antiparkinsonian Treatment and Requip ATU	
PTX 258	GSK-REQ 021076	GSK-REQ 021140	12/21/2000	2001 Tactical Plan	DX 120; DX 159
PTX 259	GSK-JEN 000158	GSK-JEN 000180	2001	Carlsson, A., "A half-century of neurotransmitter research: impact on neurology and psychiatry. Nobel lecture," <i>BioSci. Rep.</i> 21 (6): 691-710 (2001).	
PTX 260			2001	Maratos, E. C. et al., "Antiparkinsonian activity and dyskinesia risk of ropinirole and L-DOPA combination therapy in drug naive MPTP-lesioned common marmosets (Callithrix jacchus)," <i>Movement Disorders: Official Journal Of The Movement Disorder Society</i> 16 (4): 631-641 (2001).	
PTX 261	GSK-SUD 000094	GSK-SUD 000102	2001	Müngerdorf M, Sommer U, Sommer M, Reichmann H. High dose therapy with ropinirole in patients with Parkinson's Disease. <i>J. of Neural Transmission</i> 2001; 108:1309-1317.	PX 66

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 262	GSK-REQ 011654	GSK-REQ 011810	3/22/2001	GlaxoSmithKline plc Annual Report for the year ended 31st December 2000	
PTX 263	GSK-VEL 000139	GSK-VEL 000140	3/22/2001	GSK Annual Report 2000: Shareholder Return	
PTX 264	GSK-REQ 054995	GSK-REQ 054995	10/9/2001	Executive Summary of Requip 2001 ATU Study	
PTX 265	GSK-SUD 000087; GSK-VEL 000126	GSK-SUD 000093; GSK-VEL 000134	01/00/2002	Miyasaki JM, Martin W, Suchowsky O, Weiner WJ, Lang AE. Practice parameter: Initiation of treatment for Parkinson's Disease: An evidence-based review: Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2002; 58:11-17.; (http://www.neurology.org/cgi/content/full/58/1/11 , last accessed July 27, 2006).	PX 59
PTX 266	GSK-REQ 055004	GSK-REQ 055019	1/1/2002	Ziment market survey report--describes findings from interviews with 40 neurologists about DAs	
PTX 267	GSK-REQ 018822	GSK-REQ 018822	03/12/2002	Patent term extension certificate	
PTX 268			May-02	Government Affairs Update	
PTX 269	GSK-REQ 055199	GSK-REQ 055390	Aug-02	SPN Written Testimony Submitted for Funding Recommendations for the National Institutes of Health	
PTX 270	GSK-REQ 055410	GSK-REQ 055411	Aug-02	http://www.sfn.org/index.cfm?pagename=neuroscienceQuarterly_02mayjune_governmentaffairs	
PTX 271	GSK-REQ 011966	GSK-REQ 012128	10/25/2002	Parkinson's MDS Report Wave II Study	
PTX 272	GSK-REQ 063856	GSK-REQ 063861	12/31/2002	Requip Physician Study Wave II, Executive Summary	
PTX 273	GSK-REQ 061918	GSK-REQ 062010	2003	GlaxoSmithKline plc Annual Report for the year ended 31st December 2002	
PTX 274	GSK-BER 000001	GSK-BER 000006	5/2/2003	Summary of 2003 Situation Analysis	
PTX 275	GSK-REQ 025594	GSK-REQ 025620	5/2/2003	Physician-Patient Dialogue Report re RLS	
PTX 276	GSK-REQ 062255	GSK-REQ 062404	10/24/2003	U.S. Patent No. 6,569,459	
PTX 277	GSK-REQ 012129	GSK-REQ 012361	12/31/2003	NH Directors' Meeting presentation	
PTX 278	GSK-VEL 000196	GSK-VEL 000201	8/26/2004	Consumer Segmentation Study--Summary of Key Findings	
PTX 279	GSK-VEL 000071	GSK-VEL 000125	Nov-04	GlaxoSmithKline plc Annual Report for the year ended 31st December 2003	
PTX 280	GSK-VEL 000024	GSK-VEL 000043	2005	Scherer, F.M. "The Pharmaceutical Industry--Prices and Progress", <i>New England Journal of Medicine</i> , August 26, 2004; 927-932.	
PTX 281	GSK-JEN 001073	GSK-JEN 001074	2005	National Institute of Neurological Disorders and Stroke: Parkinson's Disease: Challenges, Progress and Promise	
PTX 282	GSK-SUD 000026	GSK-SUD 000030	2005	New Drug Application & Biological License Application Efficacy Supplements Approved (CY 2005)	
PTX 283	GSK-VEL 000060	GSK-VEL 000068	2005	TUPHAR Receptor Database	
PTX 284	GSK-REQ 012362	GSK-REQ 012573	3/2/2005	Högl B, Kiechl S, Willett J, Saletti M, Frauscher B, Seppi K, Müller J, Rungger G, Gasperi A, Wenning G, Poewe W. Restless Legs Syndrome: A community-based study of prevalence, severity, and risk factors. <i>Neurology</i> 2005; 64:1920-1924.	
PTX 285			04/06/2005	David, Jesse and Stewart, Marion B., "Commercial Success: Economic Principles Applied to Patent Litigation", in Gregory K. Leonard and Lauren J. Sirch, eds. <i>Economic Approaches to Intellectual Property Policy, Litigation, and Management</i> , National Economic Research Associates, 2005, pp. 195-207, p. 205.	
PTX 286			6/23/2005	GlaxoSmithKline plc Annual Report for the year ended 31st December 2004	
				Complaint, <i>Smith Kline & French Laboratories, Ltd and SmithKline Beecham Corp., d/b/a GlaxoSmithKline v. Teva Pharmaceuticals USA, Inc.</i> (Civil Action No. 05-197 GMS).	
				Parkinson's Disease- initiating patients on Ropinirole delivers long-term benefits http://www.medicalnewstoday.com/medicalnews.php?newsid=26521	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 287	GSK-SUD 000167	GSK-REQ 000174	7/00/2005	Tison F, Crochard A, Léger D, Bouée S, Lainey E, El Hasnaoui A. Epidemiology of restless legs syndrome in French adults: A nationwide survey: The INSTANT Study. <i>Neurology</i> 2005; 65:239-246.	
PTX 288	GSK-BER 000059	GSK-BER 000069	11/01/2005	Robert C. Faber, Landis on Mechanics of Claim Drafting, § 10:1.1, 5th Ed., 2005	
PTX 289	GSK-REQ 029754	GSK-REQ 029767		Impact RX--Requp RLS and PD Final POP Survey Results	
PTX 290	GSK-VEL 000204	GSK-VEL 000207	12/31/2005	Anarin Corp: Selected Data (UK GAAP-Unaudited)	
PTX 291	TEV-RQEXP 000057	TEV-RQEXP 000058	2006	Indole-derived fragments of ergot alkaloids as dopamine cogeners. 2006.	
PTX 292	GSK-JEN 000065	GSK-JEN 000679	2006	Goldberg, L. I. and J. D. Kohli. 2006. DIFFERENTIATION OF DOPAMINE RECEPTORS IN THE PERIPHERY. In <i>Dopamine Receptors</i> . Edited by C. Kaiser and J. W. Kebabian. Washington DC: American Chemical Society.	
PTX 293	GSK-JEN 000749	GSK-JEN 000754	2006	Horn, A. S. et al., "Prodrugs of some dopaminergic 2-aminotetralin: a review of their syntheses and their neurochemical profiles," <i>Eur.J.Med.Chem.</i> 16: 469-472 (2006).	
PTX 294	GSK-JEN 000766	GSK-JEN 000770	2006	Ilhan, M. et al., "TL-350, An Ergoline Derivative with Dopamine Receptor Agonist Properties," <i>J.Pharmacol.Exp.Ther.</i> 31 (1): 56-60 (2006).	
PTX 295	GSK-REQ 055027	GSK-REQ 055041	04/01/2006	Requp Attribute/Branding Research report	
PTX 296	GSK-BER 000076	GSK-BER 000095	04/01/2006	Jeffrey G. Sheldon, How to Write a Patent Application, Practising Law Institute, § 6.5, 2006	
PTX 297	GSK-SUD 000103	GSK-SUD 000115	04/01/2006	Paiwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ. Practice parameter: Treatment of Parkinson Disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. <i>Neurology</i> 2006; 66:983-995.	
PTX 298	GSK-VEL 000242	GSK-VEL 000245	May-06	DFA: Fast Track, Accelerated Approval and Priority Review	PX 60
PTX 299			07/10/2006	Expert Report of Dr. Daniel Tarsy and attachments thereto	
PTX 300	GSK-SUD 000116	GSK-SUD 000117	09/20/2006	Parkinson's Disease Background: National Institute of Neurological Disorders and Stroke, http://www.ninds.nih.gov/disorders/parkinsons_disease/background.htm .	
PTX 301	GSK-SUD 000163	GSK-SUD 000164	9/20/2006	Restless Legs Syndrome Information Page: National Institute of Neurological Disorders and Stroke, http://www.ninds.nih.gov/disorders/restless_legs/restless_legs_pr.htm .	
PTX 302	GSK-SUD 000061	GSK-SUD 000064	09/20/2006	The Michael J. Fox Foundation for Parkinson's Research, http://www.michaeljfox.org/parkinsons/ .	
PTX 303			9/22/2006	Expert Report of Egon E. Berg	PX 72, DX 157
PTX 304			09/22/2006	Expert Report of Christopher A. Velluro	PX 61
PTX 305			10/05/2006	Rebuttal Expert Report of Dr. Daniel Tarsy and attachments thereto	
PTX 306	GSK-REQ 089203	GSK-REQ 089203		"Flexible Dosing for a Chronic Disease" Ad	
PTX 307	GSK-REQ 091903	GSK-REQ 091904		"Progressive Dosing for a Progressive Disease" Ad	
PTX 308	GSK-REQ 027850	GSK-REQ 027853		AD	
PTX 309	GSK-REQ 026000	GSK-REQ 026001		Ad featuring NEJM and flexible dosing messages	
PTX 310	Velluro Ex. 10			Annual Non-U.S. Sales of Requp (in millions of \$) By Region of the World, 1999-2005	
PTX 311	GSK-VEL 000270	GSK-VEL 000460		Annual Report of GlaxoSmithKline plc for the year ended 31st December 2005	
PTX 312	Velluro Ex. 10-B			Annual Sales of Requp (in millions of \$) As Reported by GlaxoSmithKline by Region of the World, 1999-2005	
PTX 313	GSK-REQ 057968	GSK-REQ 057969		Chart showing Requp competitors	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 314				Curriculum Vitae of Egon E. Berg	
PTX 315	Velluoro Ex. 11-C			Estimated Annual Detailing and Journal Advertising Expenditures (US \$000's) For Comtan, Mirapex, and Requip, 1998-2004	
PTX 316	Velluoro Ex. 11-B			Estimated Annual Detailing and Journal Advertising Expenditures (US \$000's) For Comtan, Mirapex, and Requip, 1998-2004	
PTX 317	Velluoro Ex. 11			Estimated Annual Detailing, Journal, and PMEA Expenditures (US \$000's) Comtan, Mirapex, and Requip, 1998-2002	
PTX 318	Velluoro Ex. 3			Estimated Annual Dollar Sales of Anti-Parkinson's Drugs in the U.S. (US \$000's) By Drug Category, 1995 - YTD 2006	
PTX 319	Velluoro Ex. 11-A			Estimated Annual Marketing Expenditures of reontan, Mirapex, and Requip (US \$000's) By Marketing Type, 1998-2002	
PTX 320	Velluoro Ex. 4			Estimated Annual Total Prescriptions (TRxs) for Anti-Parkinson's Drugs in the U.S. (000's) By Drug Category, 1995 - YTD 2006	
PTX 321	Velluoro Ex. 12			Estimated Annual U.S. Dollar Sales per Extended Unit Requip and Mirapex by Strength, 1997-YTD 2006	
PTX 322	Velluoro Ex. 12-A			Estimated Annual U.S. Dollar Sales Requip and Mirapex by Strength, 1997-YTD 2006	
PTX 323	Velluoro Ex. 12-B			Estimated Compound Annual Growth Rates For Annual Dollar Sales of Anti-Parkinson's Drugs in the U.S. By Drug Category 2001 through 2005	
PTX 324	Velluoro Ex. 7-B			Estimated Compound Annual Growth Rates For Annual Dollar Sales of Anti-Parkinson's Drugs in the U.S. By Drug Category, 2003 through 2005	
PTX 325	Velluoro Ex. 7-C			Estimated Compound Annual Growth Rates For Annual Dollars Sales of Anti-Parkinson's Drugs in the U.S. By Drug Category, 1999 through 2005	
PTX 326	Velluoro Ex. 7-A			Estimated Compound Annual Growth Rates for Annual Total Prescription (TRxs) for Anti-Parkinson's Drugs in the U.S. By Drug Category, 2003 through 2005	
PTX 327	Velluoro Ex. 8-C			Estimated Compound Annual Growth Rates for Annual Total Prescription (TRxs) for Anti-Parkinson's Drugs in the U.S. By Drug Category, 1999 through 2005	
PTX 328	Velluoro Ex. 8-A			Estimated Compound Annual Growth Rates for Annual Total Prescription (TRxs) for Anti-Parkinson's Drugs in the U.S. By Drug Category 2001 through 2005	
PTX 329	Velluoro Ex. 8-B			Estimated Compound Annual Growth Rates for Annual Total Prescription (TRxs) for Anti-Parkinson's Drugs in the U.S. By Drug Category 2001 through 2005	
PTX 330	Velluoro Ex. 5			Estimated Percentage Shares of Annual Dollar Sales of Anti-Parkinson's Drugs in the U.S. By Drug Category, 1995 - YTD 2006	
PTX 331	Velluoro Ex. 6			Estimated Percentage Shares of Annual Total Prescriptions (TRxs) for Anti-Parkinson's Drugs in the U.S. By Drug Category, 1995 - YTD 2006	
PTX 332	Velluoro Ex. 5-A			Estimated Percentage Shares of Annual U.S. Dollar Sales of Anti-Parkinson's Drugs By Drug Category, 1995 - YTD 2006	
PTX 333	Velluoro Ex. 6-A			Estimated Percentage Shares of Annual U.S. Total Prescriptions (TRxs) for Anti-Parkinson's Drugs By Drug Category, 1995 YTD 2006	
PTX 334	Velluoro Ex. 13			Estimated Requip Blank Sales and Profitability 1997-YTD 2006 (US \$000's)	
PTX 335	GSK-REQ061860	GSK-REQ061861		Executive Summary of Requip 2001 ATU Study	
PTX 336	GSK-VEL 000135	GSK-VEL 000135		Dupont Heritage: Sinemet	
PTX 337	GSK-VEL 000136	GSK-VEL 000138		FDA Label and Approval History: SINEMET	
PTX 338	GSK-VEL 000234	GSK-VEL 000235		FDA Label and Approval History: Comtan	
PTX 339	GSK-VEL 000463	GSK-VEL 000464		Orange Book Detail Record Search: Pergolide Mesylate "019385"	
PTX 340	GSK-VEL 000152	GSK-VEL 000153		Mirapex ® at http://www.mirapex.com/pb/Controller.jpf	
PTX 341	GSK-VEL 000044	GSK-VEL 000070		National Institute of Neurological Disorders and Stroke: Parkinson's Disease: Hope Through Research	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Dates	Ending Dates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 342	GSK-VEL 000208	GSK-VEL 000213		Parkinson's Disease Foundation: Medications and Treatments	
PTX 343	GSK-VEL 000236	GSK-VEL 000237		Stalevo at http://www.stalevo.com	
PTX 344	GSK-VEL 000461	GSK-VEL 000462		About Stalevo at http://www.stalevo.com/info/about/what_is_stalevo.jsp	
PTX 345	Vellituro Ex. 10-A			Implied Annual SUS# Exchange Rate Sales in the U.S. Reported by GlaxoSmithKline, 1999-2005	
PTX 346	GSK-VEL 000642	GSK-VEL 000642		IMS/Verispan Data	
PTX 347	GSK-SUD 000065	GSK-SUD 000086		Mirapex [®] Package Insert	
PTX 348	GSK-REQ 088816	GSK-REQ 088825		Requip [®] "Equipped for Living" ad	
PTX 349	GSK-REQ 025995	GSK-REQ 025996		Requip [®] "Equipped for Living" ad (shorter version than others)	
PTX 350	GSK-REQ 025827	GSK-REQ 025831		Requip ad "Titrate to Achieve Maximum Therapeutic Effect" and "Flexible Titration"	
PTX 351	Vellituro Ex. 9			Requip Brand P&L as Reported by GSK (US \$000's) 1997-YTD 2006	PX 16
PTX 352	GSK-REQ 090676	GSK-REQ 090689		Requip RLS ad	
PTX 353	GSK-SUD 000126	GSK-SUD 000162		REQUIP [®] Package Insert	
PTX 354	GSK-REQ 063862	GSK-REQ 063867		Strategic Brand Plan summary	
PTX 355	GSK-REQ 057656	GSK-REQ 057659		Summary of 2004 Situation Analysis	PX 73
PTX 356	Vellituro Ex. 2			Vellituro does considered list	
PTX 357	GSK-VEL 000246	GSK-VEL 000248		Letter to SK B from FDA re Supplemental Application for NDA 20-658	
PTX 358	GSK-REQ 020979	GSK-REQ 020979	2001	2001 Business Plan Review	
PTX 359	GSK-REQ 020980	GSK-REQ 021018	02/05/2001	Requip Business Review	
PTX 360	GSK-REQ 021019	GSK-REQ 021075	06/22/1905	Requip 2000 Situation Analysis	
PTX 361	GSK-REQ 021141	GSK-REQ 021166		Market 3/1 Plan 2001-2003: United States	
PTX 362	GSK-REQ 021167	GSK-REQ 021193		Market 3/1 Plan 2001-2003: United States	
PTX 363	GSK-REQ 025074	GSK-REQ 025075		Requip Revenue Consensus Forecast (actuals in red)	
PTX 364	GSK-REQ 025076	GSK-REQ 025160	7/26/2000	Requip Update	
PTX 365	GSK-REQ 025161	GSK-REQ 025216		Requip 2001 Tactical Plan	
PTX 366	GSK-REQ 025217	GSK-REQ 025291	Jan-01	NeuroHealth Sales Force Training, Dallas, TX	
PTX 367	GSK-REQ 025292	GSK-REQ 025347	2001	Requip [®] (ropinirole HCl)	
PTX 368	GSK-REQ 025348	GSK-REQ 025393	8/21/2002	NH Director's Meeting	
PTX 369	GSK-REQ 025394	GSK-REQ 025444	Oct-02	NH Director's Meeting	
PTX 370	GSK-REQ 025445	GSK-REQ 025499	Oct-02	NH Director's Meeting	
PTX 371	GSK-REQ 025500	GSK-REQ 025551	2-Oct	NH Director's Meeting	
PTX 372	GSK-REQ 025552	GSK-REQ 025593	8/21/2002	NH Director's Meeting	
PTX 373	GSK-REQ 025594	GSK-REQ 025620	8/21/2002	NH Director's Meeting	
PTX 374	GSK-REQ 025621	GSK-REQ 025630		Requip is Making Inroads in Frequency of Past Month Use Vs. Mirapex	
PTX 375	GSK-REQ 025631	GSK-REQ 025673		Realizing the Power of NeuroHealth: Requip Clinical Specialist Brand Strategy Q & A	
PTX 376	GSK-REQ 025674	GSK-REQ 025739		Brand Overview and Tactical Plan for Requip	
PTX 377	GSK-REQ 025740	GSK-REQ 025774	2003	2003 Tactical Overview: National Managers Meeting	
PTX 378	GSK-REQ 025775	GSK-REQ 025787		Requip PD 2002-2003 Planning	
PTX 379	GSK-REQ 025788	GSK-REQ 025788		Picture of Requip Notepad	

EXHIBIT 7
TO PROPOSED ORDER

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 380	GSK-REQ 025789	GSK-REQ 025789		Picture of Requip Pen	
PTX 381	GSK-REQ 025790	GSK-REQ 025795		A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa	
PTX 382	GSK-REQ 025796	GSK-REQ 025802		A guide to Parkinson's Disease and the role of REQUIP	
PTX 383	GSK-REQ 025803	GSK-REQ 025804		Requip ® (Ropinirole HCl): A Flexible Dosing Range for Patients' Individual Needs	
PTX 384	GSK-REQ 025805	GSK-REQ 025806		2001 National Parkinson Foundation Patient Survey Highlights	
PTX 385	GSK-REQ 025807	GSK-REQ 025807		Impact of Dyskinesia: Data from the 2001 National Parkinson Foundation Patient Survey	
PTX 386	GSK-REQ 025808	GSK-REQ 025808		REQUIP ® ropinirole HCl	
PTX 387	GSK-REQ 025809	GSK-REQ 025809		In Parkinson's Disease START WITH REQUIP for effective monotherapy demonstrated in a five-year study	
PTX 388	GSK-REQ 025810	GSK-REQ 025810		In Parkinson's Disease START WITH REQUIP for a low risk of dyskinesia	
PTX 389	GSK-REQ 025811	GSK-REQ 025817	4/21/2001	American Academy of Neurology Annual Meeting GlaxoSmithKline Parkinson's Disease Video	
PTX 390	GSK-REQ 025818	GSK-REQ 025826		Highlights from Revised Parkinson's Disease Treatment Guidelines	
PTX 391	GSK-REQ 025832	GSK-REQ 025841		Requip "Equipped for Living" Ad	
PTX 392	GSK-REQ 025842	GSK-REQ 025844		Requip "Equipped for Living" Ad	
PTX 393	GSK-REQ 025845	GSK-REQ 025846		Requip "Equipped for Living" Ad	
PTX 394	GSK-REQ 025847	GSK-REQ 025858		A guide to Parkinson's Disease and the role of REQUIP	
PTX 395	GSK-REQ 025859	GSK-REQ 025868		Requip "Equipped for Living" Ad	
PTX 396	GSK-REQ 025869	GSK-REQ 025870		Requip "Equipped for Living" Ad	
PTX 397	GSK-REQ 025871	GSK-REQ 025871		"Equipped to Help Manage Tremor" Ad	
PTX 398	GSK-REQ 025872	GSK-REQ 025872		"Compliments of Requip ® ropinirole HCl"	
PTX 399	GSK-REQ 025873	GSK-REQ 025877		"Requip ropinirole HCl 3-mg tablet"	
PTX 400	GSK-REQ 025878	GSK-REQ 025879		Unified Parkinson's Disease Rating Scale	
PTX 401	GSK-REQ 025880	GSK-REQ 025886		"Equipped to Decrease Time "off" Ad	
PTX 402	GSK-REQ 025887	GSK-REQ 025887		"Time to Refill" Ad	
PTX 403	GSK-REQ 025888	GSK-REQ 025888		A Guide to the Treatment of Parkinson's Disease	
PTX 404	GSK-REQ 025889	GSK-REQ 025952		Requip "Equipped for Living" Ad	
PTX 405	GSK-REQ 025953	GSK-REQ 025960		REQUIP (ropinirole HCl) and other treatment strategies for the management of Parkinson's Disease	
PTX 406	GSK-REQ 025961	GSK-REQ 025961		CD: Parallax Productions: Understanding dyskinesia	
PTX 407	GSK-REQ 025962	GSK-REQ 025991		Requip "Equipped for Living" Ad	
PTX 408	GSK-REQ 025992	GSK-REQ 025992		An Educational Video for Primary Care Physicians: Diagnosing & Initiation Treatment in Early Parkinson's Disease	
PTX 409	GSK-REQ 025993	GSK-REQ 025994		Picture of Requip Notepad	
PTX 410	GSK-REQ 025995	GSK-REQ 025996		Picture of Requip pill case	
PTX 411	GSK-REQ 025997	GSK-REQ 025997		Requip "Equipped for Living" ad	
PTX 412	GSK-REQ 025998	GSK-REQ 025999		Requip Clip Deal Detail	
PTX 413	GSK-REQ 136060	GSK-REQ 136069		Picture of Requip Pen	
PTX 414	GSK-BER 000616	GSK-BER 000631	10/22/1986	REQUIP Data Table of Contents	
PTX 415	GSK-BER 000632	GSK-BER 000639	12/23/1992	European Patent 0 113 964 B1	
PTX 416			9/22/2006	European Patent 0 299 602 B1	
PTX 417			9/22/2006	Expert Report of Professor Paul A. Bartlett, Ph. D.	
PTX 418			9/22/2006	Expert Report of Professor Peter George Jenner	
				Expert Report of Lewis Sudarsky, M.D.	PX 67
PTX 419	http://www.fda.gov/cder/foi/appleletter/2005/020658s0131ur.pdf		5/4/2005	Letter from Dr. Russell Katz to Dr. Rogers re: Supplemental ANDA	
PTX 420	GSK-VEL 000269	GSK-VEL 000269		Verispan Data	
PTX 421	GSK-VEL 000641	GSK-VEL 000641		IMS Data	

**EXHIBIT 7
TO PROPOSED ORDER**

GSK EXHIBIT LIST

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Depo. Exh. No.
PTX 422	GSK-REQ 011531	GSK-REQ 011531	9/9/1998	Letter from Ronald R. Wilson of Dept. of Health to Stephen Kunin re: U.S. Patent Application No. 4,452,808	
PTX 423	http://www.fda.gov/CDER/foi/nda/97/020658ap_reqip_a_pltr.pdf		9/19/1997	Letter from Robert Temple, M.D. of Dept. of Health to Eloise R. Scott of SmithKline Beecham Pharmaceuticals re: drug application	
PTX 424	GSK-BAR 000107	GSK-BAR 000115		Cannon JG, Hatheway GJ. Centrally acting emetics. 10. Rigid dopamine congeners derived from octahydrobenzo[<i>f</i>]quinoline. <i>J Med Chem</i> 1976; 19(8):987-993.	
PTX 425				Cannon JG, Lee T, Goldman HD. Cerebral dopamine agonist properties of some 2-aminoetralin derivatives after peripheral and intracerebral administration. <i>J Med Chem</i> 1977; 20(9):1111-1116.	
PTX 426				Cannon JG, Perez Z, Long JP, Rusterholz DB, Flynn JR, Costall B et al. N-Alkyl derivatives of (+/-)- α -methylhydopamine. <i>J Med Chem</i> 1979; 22(8):901-907.	PX 40
PTX 427				Cannon JG. Dopamine Congeners Derived from the Benzo[<i>f</i>]quinoline Ring. 1979. p. 87-94.	PX 46
PTX 428				Cannon JG, Perez JA, Pease JP, Long JP, Flynn JR, Rusterholz DB et al. Comparison of biological effects of N-alkylated congeners of beta-phenethylamine derived from 2-aminoetralin, 2-aminoindan, and 6-aminobenzocycloheptene. <i>J Med Chem</i> 1980; 23(7):745-749.	
PTX 429				Rusterholz DB, Long JP, Flynn JR, Cannon JG, Lee T, Pease JP et al. Dopaminergic effects of non-hydroxylated rigid analogs of apomorphine. <i>Eur J Pharmacol</i> 1979; 55(1):73-82.	
PTX 430				Sindelar RD, Mott J, Barfknecht CF, Americ SP, Flynn JR, Long JP et al. 2-Amino-4,7-dimethoxyindan derivatives: synthesis and assessment of dopaminergic and cardiovascular actions. <i>J Med Chem</i> 1982; 25(7):858-864.	
PTX 431			2006	Article entitled, "Initial Treatment of Parkinson's Disease" by D. Tarsy published in Current Treatment Options in Neurology 2006. 8:224-235	PX 64
PTX 432	TEV-RQEXP000349	TEV-RQEXP000355	2001	Article entitled, "Choosing Dopamine Agonists in Parkinson's Disease" by E. Tan and J. Jankovic	PX 65
PTX 433	GSK-REQ 025646	GSK-REQ 025651	2003	2003 Tactical Overview	PX 74
PTX 434				Curriculum Vitae of Paul A. Bartlett	DX 141
PTX 435				Curriculum Vitae of Peter G. Jenner	
PTX 436				Curriculum Vitae of Lewis Sudarsky, M.D.	DX 155
PTX 437				Curriculum Vitae of Christopher A. Velluto	DX 157

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**KEY TO TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

A	Authenticity (including unidentified handwriting or other marking)
H	Hearsay
IN	Incomplete
F	Foreign Language
T	Not timely produced
B	Best evidence
IL	Illegible
M	Missing-no copy provided or properly identified for which to make objections, all objections preserved
MI	Misdescription
MD	Multiple documents
R	Relevance including "foundation" objections and other relevance conditional on sponsoring testimony

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 1	GSK-REQ 026002	GSK-REQ 026551	8/17/1976 - 8/2/1978		H, IN
PTX 2	GSK- REQ098179	GSK- REQ98333	10/28/80 - 8/17/1982		A, H, IN, R
PTX 3	GSK- REQ096872	GSK- REQ096992	4/24/1981 - 7/14/1982		A, H, IN, R
PTX 4	GSK-REQ 026552	GSK-REQ 027156	9/25/1981 - 12/27/1983		A, H, IN, R
PTX 5	GSK-REQ 004689	GSK-REQ 004697	12/31/1981		H, R
PTX 6	GSK- REQ097492	GSK- REQ097630	5/14/1982 - 1/4/1983		A, H, IN, R
PTX 7	GSK- REQ098459	GSK- REQ098575	8/3/1982 - 7/28/1983		A, H, IN, R
PTX 8	GSK-REQ 023535	GSK-REQ 023536	8/12/1982		A, H, R
PTX 9	GSK-REQ 013586	GSK-REQ 013588	8/13/1982		A, H, R
PTX 10	GSK-REQ 024341	GSK-REQ 024345	8/25/1982		A, H, R
PTX 11	GSK-REQ 011577	GSK-REQ 011578	12/6/1982		
PTX 12	GSK-REQ 094320	GSK-REQ 094320	12/6/1982		
PTX 13	GSK-REQ 014577	GSK-REQ 014584	12/7/1982		
PTX 14	GSK-REQ 094317	GSK-REQ 094433	12/7/1982 - 08/16/1985		MI, MD, A, H, R
PTX 15	GSK-REQ 007047	GSK-REQ 007049	7/1/1983		
PTX 16	GSK-REQ 007068	GSK-REQ 007069	8/21/1984		H, R
PTX 17	GSK-REQ 005905	GSK-REQ 005908	1/1/1985		
PTX 18	GSK-REQ 007942	GSK-REQ 007947	10/14/1985		H, R
PTX 19	GSK-REQ 014500	GSK-REQ-014504	11/8/1985		H, R
PTX 20	GSK-REQ 018136	GSK-REQ 018141	12/9/1985		H, R
PTX 21	GSK-REQ 006741	GSK-REQ 006749	1/1/1986		
PTX 22	GSK-REQ 014449	GSK-REQ 014457	1/9/1986		H, R
PTX 23	GSK-REQ 000208	GSK-REQ 000426	2/7/1986		H
PTX 24	GSK-REQ 017394	GSK-REQ 017624	3/18/1986		A, H, R, IN, MD
PTX 25	GSK-REQ 014391	GSK-REQ 014406	7/16/1986		H, R, IN
PTX 26	GSK-REQ 001028	GSK-REQ 001071	7/16/1986		H, R
PTX 27	GSK-REQ 004891	GSK-REQ 004899	1/1/1987		H, R, MD
PTX 28	GSK-REQ 003935	GSK-REQ 003961	3/1/1987		H, R
PTX 29	GSK-REQ 013537	GSK-REQ 013543	4/6/1987		H, R
PTX 30	GSK-REQ 020735	GSK-REQ20973	9/1/1987		H
PTX 31	GSK-REQ 004067	GSK-REQ 004071	10/12/1987		H, R, IN
PTX 32	GSK-REQ136031	GSK-REQ136034	12/7/1987		H, R, IN, A
PTX 33	GSK-REQ 007277	GSK-REQ 007284	3/3/1988		H, R, IN
PTX 34	GSK-REQ 008156	GSK-REQ 008169	3/16/1988		H, R
PTX 35	GSK-REQ 020566	GSK-REQ 020570	5/19/1988		
PTX 36	GSK-REQ 019829	GSK-REQ 019834	5/19/1988		
PTX 37	GSK-REQ 094434	GSK-REQ 094657	5/19/1988 - 04/25/1989		MI, MD, A, H
PTX 38	GSK-REQ 001371	GSK-REQ 001382	10/00/1988		A, H, R, IN

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 39	GSK-REQ 004006	GSK-REQ 004040	3/1/1989		H, R
PTX 40	GSK-REQ 000074	GSK-REQ 000085	5/1/1989		H, R
PTX 41	GSK-REQ 001195	GSK-REQ 001200	5/1/1989		H, R
PTX 42	GSK-REQ 004183	GSK-REQ 004260	5/1/1989		H, R
PTX 43	GSK-REQ 013611	GSK-REQ 013618	7/23/1990		H, R
PTX 44	GSK-REQ 126009	GSK-REQ 126024	3/1/1994		H, R
PTX 45	GSK-REQ 014656	GSK-REQ 014658	5/19/1998		MD, MI
PTX 46	GSK-JEN 001317	GSK-JEN 001323	5/24/2000		R
PTX 47	GSK-REQ 011473	GSK-REQ 014558	2/21/2005		M
PTX 48			5/5/2006		
PTX 49			5/18/2006		
PTX 50	GSK-REQ 013633	GSK-REQ 013634	unknown		H, R
PTX 51	TEV-RQ 007302	TEV-RQ 007320	8/6/2001		H, R
PTX 52	TEV-RQ 000807	TEV-RQ 000813	12/22/2004		H, R
PTX 53	TEV-RQ 00827	TEV-RQ 000827	11/24/2004		R
PTX 54			02/21/2005		R
PTX 55	TEV-RQ 007323	TEV-RQ 007324	01/07/2003		R
PTX 56	TEV-RQ 007193	TEV-RQ 007193			H, R
PTX 57	GSK-REQ 024351	GSK-REQ 024354	9/11/1984		A, H, R
PTX 58	GSK-REQ 011503	GSK-REQ 011503	7/26/1989		
PTX 59			10/3/2005		MD, R
PTX 60			10/31/2005		R
PTX 61			4/10/2006		R
PTX 62			5/16/2006		R
PTX 63			6/9/2006		R
PTX 64	TEV-RQ 000001	TEV-RQ 006053			R
PTX 65	TEV-RQ 000815	TEV-RQ 000819	12/22/2004		R
PTX 66	GSK-REQ 094245	GSK-REQ 094254			H, R
PTX 67	GSK-REQ 136050	GSK-REQ 136059			H, R
PTX 68	GSK-REQ 011486	GSK-REQ 011486			
PTX 69	GSK-REQ 014560	GSK-REQ 014560	5/19/1988		
PTX 70			4/11/2006		
PTX 71	GSK-REQ 022444	GSK-REQ 022490	9/1/1989		H, R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 72	GSK-REQ 094246A	GSK-REQ 94246A			H, R
PTX 73			5/22/2006		MD, R
PTX 74					
PTX 75					
PTX 76	GSK-REQ 018659	GSK-REQ 018699	6/5/1984		
PTX 77	GSK-REQ 018613	GSK-REQ 018658	4/25/1989		
PTX 78					M
PTX 79					M
PTX 80	GSK-VEL 000249	GSK-VEL 000259	1948		R
PTX 81			1968		M
PTX 82			1972		M
PTX 83			1974		M
PTX 84	GSK-JEN 000052	GSK-JEN 000060	1975		H, R
PTX 85	GSK-JEN 000294	GSK-JEN 000300	1975		R
PTX 86			1975		M
PTX 87	GSK-JEN 000771	GSK-JEN 000779	1975		R
PTX 88	GSK-JEN 000308	GSK-JEN 000319	1976		R
PTX 89	GSK-JEN 000940	GSK-JEN 000950	1976		R
PTX 90			1976		
PTX 91			1977		R
PTX 92	GSK-JEN 000521; GSK-BAR 000066; GSK-BAR 000077	GSK-JEN 000541; GSK- BAR 000076; GSK- BAR 000086	1977		R
PTX 93	GSK-JEN 001189	GSK-JEN 001192	1977		R
PTX 94	GSK-JEN 001193	GSK-JEN 001196	1977		R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 95			1977		M
PTX 96	GSK-JEN 000061; TEV-RQEXP 000047; GSK-BAR 000142	GSK-JEN 000066; TEV- RQEXP 000052; GSK- BAR 000147	1978		
PTX 97	GSK-JEN 000589	GSK-JEN 000597	1978		R
PTX 98	GSK-JEN 000564	GSK-JEN 000588	1978		R
PTX 99			1978		M
PTX 100	GSK-JEN 000854	GSK-JEN 000855	1978		R
PTX 101	GSK-JEN 000972	GSK-JEN 000976	1978		R
PTX 102	GSK-JEN 001298	GSK-JEN 001304	1978		R
PTX 103	GSK-JEN 000552	GSK-JEN 000558	1979		R
PTX 104	GSK-JEN 000783	GSK-JEN 000786	1979		R
PTX 105	GSK-JEN 000798	GSK-JEN 000801	1979		R
PTX 106	GSK-JEN 000873	GSK-JEN 000877	1979		R
PTX 107			1979		M
PTX 108	GSK-JEN 000010	GSK-JEN 000020	1980		R
PTX 109	GSK-JEN 000320	GSK-JEN 000336	1980		R
PTX 110	GSK-JEN 000734	GSK-JEN 000738	1980		R
PTX 111	GSK-JEN 000745	GSK-JEN 000748	1980		R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 112	GSK-JEN 000981	GSK-JEN 000988	1980		R
PTX 113	GSK-JEN 001089	GSK-JEN 001173	1980		R
PTX 114	GSK-JEN 001209	GSK-JEN 001214	1980		R
PTX 115	GSK-JEN 001253	GSK-JEN 001255	1980		R
PTX 116	GSK-JEN 000067; GSK-BAR 000148	GSK-JEN 000071; GSK- BAR 000150	1981		
PTX 117	GSK-JEN 000072; GSK-BAR 000001	GSK-JEN 000079; GSK- BAR 000006	1981		
PTX 118	GSK-JEN 000080	GSK-JEN 000084	1981		R
PTX 119	GSK-JEN 000362	GSK-JEN 000369	1981		R
PTX 120	GSK-JEN 000692	GSK-JEN 000699	1981		R
PTX 121	GSK-JEN 000700; GSK-BAR 000170	GSK-JEN 000705; GSK- BAR 000175	1981		R
PTX 122	GSK-JEN 000780	GSK-JEN 000782	1981		R
PTX 123			1981		M
PTX 124	GSK-JEN 001215	GSK-JEN 001218	1981		H, R
PTX 125	GSK-JEN 001235; GSK-BAR 000087	GSK-JEN 001243; GSK- BAR 000095	1981		R
PTX 126	TEV-RQEXP 000005	TEV-RQEXP 000014	1982		
PTX 127			1982		
PTX 128	GSK-JEN 000085	GSK-JEN 000099	1982		R
PTX 129	GSK-JEN 000181	GSK-JEN 000191	1982		R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 130	GSK-JEN 000148	GSK-JEN 000157	1982		R
PTX 131	GSK-JEN 000370	GSK-JEN 000377	1982		R
PTX 132	GSK-JEN 000378	GSK-JEN 000404	1982		R
PTX 133	GSK-JEN 000686	GSK-JEN 000691	1982		R
PTX 134	GSK-JEN 000808	GSK-JEN 000821	1982		R
PTX 135	GSK-JEN 000822	GSK-JEN 000828	1982		R
PTX 136	GSK-JEN 000878	GSK-JEN 000885	1982		R
PTX 137	GSK-JEN 000894	GSK-JEN 000905	1982		R
PTX 138	GSK-JEN 000931	GSK-JEN 000933	1982		R
PTX 139	GSK-JEN 001024	GSK-JEN 001033	1982		R
PTX 140	GSK-JEN 001174	GSK-JEN 001179	1982		R
PTX 141	GSK-JEN 001291	GSK-JEN 001297	1982		R
PTX 142	GSK-VEL 000202	GSK-VEL 000203	1/1/1982		A, H, R
PTX 143	GSK-BER 000567	GSK-BER 000571	Sep-82		H, R, IN, IL
PTX 144			1983		M
PTX 145	GSK-BAR 000026	GSK-BAR 000055	1983		R
PTX 146	GSK-JEN 000127	GSK-JEN 000133	1983		R
PTX 147	GSK-JEN 000435	GSK-JEN 000446	1983		R
PTX 148	GSK-JEN 000405	GSK-JEN 000434	1983		R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 149	GSK-JEN 000447	GSK-JEN 000460	1983		R
PTX 150	GSK-JEN 000542	GSK-JEN 000551	1983		R
PTX 151	GSK-JEN 000836	GSK-JEN 000841	1983		R
PTX 152	GSK-JEN 000934	GSK-JEN 000939	1983		R
PTX 153	GSK-JEN 000989	GSK-JEN 000994	1983		R
PTX 154	GSK-BER 000096	GSK-BER 000121	1983		A, H, R, IN
PTX 155	GSK-JEN 000028	GSK-JEN 000044	1984		H, R
PTX 156	GSK-JEN 000100; TEV-RQEXP 000053; GSK-BAR 000122	GSK-JEN 000105; TEV-RQEXP 000056; GSK-BAR 000125	1984		
PTX 157	GSK-JEN 000286	GSK-JEN 000293	1984		R
PTX 158	GSK-JEN 000337	GSK-JEN 000354	1984		R
PTX 159	GSK-JEN 000461	GSK-JEN 000467	1984		R
PTX 160	GSK-JEN 000598	GSK-JEN 000605	1984		R
PTX 161	GSK-JEN 000606	GSK-JEN 000615	1984		R
PTX 162	GSK-JEN 000680	GSK-JEN 000685	1984		F
PTX 163			1984		M
PTX 164	GSK-JEN 000802	GSK-JEN 000807	1984		R
PTX 165			1984		M
PTX 166	GSK-JEN 000906	GSK-JEN 000912	1984		R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 167	GSK-JEN 001075	GSK-JEN 001088	1984		R
PTX 168	GSK-JEN 001048	GSK-JEN 001061	1984		R
PTX 169	GSK-JEN 001219	GSK-JEN 001234	1984		R
PTX 170	GSK-JEN 001244	GSK-JEN 001252	1984		R
PTX 171	TEV-RQEXP 000358	TEV-RQEXP 000469	1985		
PTX 172	GSK-JEN 000192	GSK-JEN 000243	1985		R
PTX 173	GSK-JEN 000244	GSK-JEN 000280	1985		R
PTX 174	GSK-JEN 000281	GSK-JEN 000285	1985		R
PTX 175	GSK-JEN 000305	GSK-JEN 000307	1985		R
PTX 176	GSK-JEN 000510	GSK-JEN 000514	1985		R
PTX 177	GSK-JEN 000739	GSK-JEN 000744	1985		R
PTX 178	GSK-JEN 000856	GSK-JEN 000864	1985		R
PTX 179	GSK-JEN 000967	GSK-JEN 000971	1985		R
PTX 180	GSK-JEN 001180	GSK-JEN 001188	1985		R
PTX 181	GSK-JEN 000106; TEV-RQEXP 000249; GSK-REQ 020655; GSK-BAR 000126	GSK-JEN 000112; TEV-RQEXP 000254; GSK-REQ 020660; GSK-BAR 000132	1986		
PTX 182	GSK-JEN 000134	GSK-JEN 000139	1986		H, R
PTX 183	GSK-JEN 000829	GSK-JEN 000835	1986		H, R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 184	GSK-JEN 000865	GSK-JEN 000872	1986		H, R
PTX 185	GSK-JEN 000913	GSK-JEN 000921	1986		H, R
PTX 186	GSK-JEN 001000	GSK-JEN 001007	1986		H, R
PTX 187	GSK-JEN 001256	GSK-JEN 001268	1986		H, R
PTX 188	GSK-JEN 001269	GSK-JEN 001279	1986		H, R
PTX 189	GSK-SUD 000016	GSK-SUD 000017	1986		H, R, IN
PTX 190	GSK-JEN 000021	GSK-JEN 000027	1987		H, R
PTX 191	GSK-JEN 000143	GSK-JEN 000147	1987		H, R
PTX 192	GSK-JEN 000483	GSK-JEN 000487	1987		H, R
PTX 193	GSK-JEN 000616	GSK-JEN 000620	1987		H, R
PTX 194	GSK-JEN 000621	GSK-JEN 000635	1987		H, R
PTX 195	GSK-JEN 000712	GSK-JEN 000733	1987		H, R
PTX 196	GSK-JEN 000787	GSK-JEN 000797	1987		H, R
PTX 197	GSK-JEN 000922	GSK-JEN 000930	1987		H, R
PTX 198	GSK-JEN 000995	GSK-JEN 000999	1987		H, R
PTX 199	GSK-JEN 001008	GSK-JEN 001013	1987		H, R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 200	GSK-JEN 001280	GSK-JEN 001290	1987		H, R
PTX 201	GSK-BER 000007	GSK-BER 000019	07/21/1987		R
PTX 202	GSK-JEN 000001	GSK-JEN 000009	1988		H, R
PTX 203	GSK-JEN 000113	GSK-JEN 000120	1988		H, R
PTX 204	GSK-JEN 000497	GSK-JEN 000509	1988		H, R
PTX 205	GSK-JEN 000654	GSK-JEN 000664	1988		H, R
PTX 206	GSK-JEN 000636	GSK-JEN 000653	1988		H, R
PTX 207	GSK-JEN 000706	GSK-JEN 000711	1988		H, R
PTX 208	GSK-JEN 001309	GSK-JEN 001316	1988		M
PTX 209	GSK-JEN 001034	GSK-JEN 001047	1988		H, R
PTX 210	GSK-JEN 000476	GSK-JEN 000482	1989		H, R
PTX 211	GSK-JEN 000488	GSK-JEN 000496	1989		H, R
PTX 212	GSK-JEN 000559	GSK-JEN 000563	1989		H, R
PTX 213	GSK-JEN 000842	GSK-JEN 000849	1989		H, R
PTX 214	GSK-JEN 000951	GSK-JEN 000957	1989		H, R
PTX 215	GSK-JEN 000977	GSK-JEN 000980	1989		H, R
PTX 216	GSK-VEL 000180	GSK-VEL 000180	12/12/1989		M, R
PTX 217	GSK-JEN 000045	GSK-JEN 000051	1990		H, R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 218			1990		M
PTX 219	GSK-VEL 000181	GSK-VEL 000195	1990		H, R, IN
PTX 220	GSK-JEN 000355	GSK-JEN 000361	1990		H, R
PTX 221	GSK-JEN 000468	GSK-JEN 000475	1990		H, R
PTX 222	GSK-JEN 000515	GSK-JEN 000520	1990		H, R
PTX 223	GSK-JEN 000850	GSK-JEN 000853	1990		H, R
PTX 224	GSK-JEN 000886	GSK-JEN 000893	1990		H, R
PTX 225	GSK-JEN 000755	GSK-JEN 000760	1991		H, R
PTX 226	GSK-JEN 000761	GSK-JEN 000765	1991		H, R
PTX 227	GSK-JEN 000958	GSK-JEN 000966	1991		H, R
PTX 228	GSK-JEN 000121	GSK-JEN 000126	1992		H, R
PTX 229			1992		M
PTX 230	GSK-JEN 000140	GSK-JEN 000142	1992		H, R
PTX 231			1993		H, R
PTX 232	GSK-JEN 001014	GSK-JEN 001023	1993		H, R
PTX 233			1995		M
PTX 234			1995		M

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 235	GSK-JEN 001203	GSK-JEN 001208	1995		H, R
PTX 236	GSK-JEN 001197	GSK-JEN 001202	1996		H, R, IN
PTX 237	GSK-VEL 000238	GSK-VEL 000241	4/22/1996		A, H, R
PTX 238	GSK-BER 000020	GSK-BER 000030	12/17/1996		R
PTX 239	GSK-VEL 000154	GSK-VEL 000179	Jul-97		A, H, R
PTX 240	GSK-VEL 000001	GSK-VEL 000023	Sep-97		A, H, R
PTX 241	GSK-JEN 000301	GSK-JEN 000304	1998		H, R
PTX 242			1998		M
PTX 243	GSK-JEN 001062	GSK-JEN 001072	1998		H, R
PTX 244	GSK-SUD 000055	GSK-SUD 000060	10/00/1998		H, R
PTX 245	GSK-SUD 000031	GSK-SUD 000040	10/08/1998		H, R
PTX 246	GSK-SUD 000041	GSK-SUD 000054	10/15/1998		H, R
PTX 247	GSK-VEL 000149	GSK-VEL 000151	10/19/1998		A, H, R
PTX 248	GSK-SUD 000008	GSK-SUD 000015	1999		H, R
PTX 249	GSK-VEL 000147	GSK-VEL 000148	7/26/1999		H, R
PTX 250	GSK-VEL 000232	GSK-VEL 000233	10/19/1999		R
PTX 251	GSK-JEN 001305	GSK-JEN 001308	2000		H, R, F
PTX 252	GSK-REQ 089278	GSK-REQ 089294	2000		H, R
PTX 253	GSK-REQ 092494	GSK-REQ 092513	2000		H, R, MD
PTX 254	GSK-VEL 000214	GSK-VEL 000231	Mar-00		H, R
PTX 255	GSK-SUD 000118; GSK-REQ092494	GSK-SUD 000125; GSK-REQ092513	05/18/2000		H, R
PTX 256	GSK-VEL 000141	GSK-VEL 000146	5/22/2000		H, R
PTX 257	GSK-REQ058447	GSK-REQ058571	06/29/2000		H, R
PTX 258	GSK-REQ 021076	GSK-REQ 021140	12/21/2000		H
PTX 259	GSK-JEN 000158	GSK-JEN 000180	2001		H, R
PTX 260			2001		M

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 261	GSK-SUD 000094	GSK-SUD 000102	2001		H, R
PTX 262	GSK-REQ 011654	GSK-REQ 011810	3/22/2001		
PTX 263	GSK-VEL 000139	GSK-VEL 000140	3/22/2001		IN, R
PTX 264	GSK-REQ 054995	GSK-REQ 054995	10/9/2001		H, R
PTX 265	GSK-SUD 000087; GSK-VEL 000126	GSK-SUD 000093; GSK-VEL 000134	01/00/2002		H, R
PTX 266	GSK-REQ 055004	GSK-REQ 055019	1/1/2002		H, R
PTX 267	GSK-REQ 018822	GSK-REQ 018822	03/12/2002		MI
PTX 268			May-02		H, R
PTX 269	GSK-REQ 055199	GSK-REQ 055390	Aug-02		H, R
PTX 270	GSK-REQ 055410	GSK-REQ 055411	10/25/2002		H, R
PTX 271	GSK-REQ 011966	GSK-REQ 012128	12/31/2002		
PTX 272	GSK-REQ063856	GSK-REQ063861	2003		A, H, R
PTX 273	GSK-REQ 061918	GSK-REQ 062010	5/2/2003		H, R
PTX 274	GSK-BER 000001	GSK-BER 000006	5/27/2003		R
PTX 275	GSK-REQ025594	GSK-REQ025620	08/12/2003		H, R
PTX 276	GSK-REQ 062255	GSK-REQ 062404	10/24/2003		H, R
PTX 277	GSK-REQ 012129	GSK-REQ 012361	12/31/2003		
PTX 278	GSK-VEL 000196	GSK-VEL 000201	8/26/2004		H, R
PTX 279	GSK-VEL 000071	GSK-VEL 000125	Nov-04		H, R
PTX 280	GSK-VEL 000024	GSK-VEL 000043	2005		H, R
PTX 281	GSK-JEN 001073	GSK-JEN 001074	2005		A, H, R
PTX 282	GSK-SUD 000026	GSK-SUD 000030	2005		H, R
PTX 283	GSK-VEL 000260	GSK-VEL 000268	2005		IN, H, R
PTX 284	GSK-REQ 012362	GSK-REQ 012573	3/2/2005		
PTX 285			04/06/2005		
PTX 286			6/23/2005		H, R
PTX 287	GSK-SUD 000167	GSK-REQ 000174	7/00/2005		H, R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 288	GSK-BER 000059	GSK-BER 000069	11/01/2005		H, R, IN
PTX 289	GSK-REQ 029754	GSK-REQ 029767			H, R
PTX 290	GSK-VEL 000204	GSK-VEL 000207	12/31/2005		A, H, R
PTX 291	TEV-RQEXP 000057	TEV-RQEXP 000058	2006		
PTX 292	GSK-JEN 000665	GSK-JEN 000679	2006		R, IN, MI
PTX 293	GSK-JEN 000749	GSK-JEN 000754	2006		MI, R
PTX 294	GSK-JEN 000766	GSK-JEN 000770	2006		MI, R
PTX 295	GSK-REQ 055027	GSK-REQ 055041	04/01/2006		A, H, R
PTX 296	GSK-BER 000076	GSK-BER 000095	04/01/2006		A, H, R, IN
PTX 297	GSK-SUD 000103	GSK-SUD 000115	04/01/2006		H, R
PTX 298	GSK-VEL 000242	GSK-VEL 000245	May-06		H, R
PTX 299			07/10/2006		
PTX 300	GSK-SUD 000116	GSK-SUD 000117	09/20/2006		
PTX 301	GSK-SUD 000163	GSK-SUD 000164	9/20/2006		R
PTX 302	GSK-SUD 000061	GSK-SUD 000064	09/20/2006		
PTX 303			9/22/2006		H, R, MD
PTX 304			09/22/2006		H, R, MD
PTX 305			10/05/2006		
PTX 306	GSK-REQ 089203	GSK-REQ 089203			H, R
PTX 307	GSK-REQ 091903	GSK-REQ 091904			A, H, R, MI
PTX 308	GSK-REQ 027850	GSK-REQ 027853			A, H, R, MI
PTX 309	GSK-REQ 026000	GSK-REQ 026001			A, H, R, MI
PTX 310	Velturo Ex. 10				H, R
PTX 311	GSK-VEL 000270	GSK-VEL 000460			M
PTX 312	Velturo Ex. 10-B				H, R
PTX 313	GSK-REQ 057968	GSK-REQ 057969			A, H, R
PTX 314					H, R
PTX 315	Velturo Ex. 11-C				H, R
PTX 316	Velturo Ex.11-B				H, R
PTX 317	Velturo Ex. 11				H, R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 318	Velturo, Ex. 3				H, R
PTX 319	Velturo Ex. 11-A				H, R
PTX 320	Velturo Ex. 4				H, R
PTX 321	Velturo Ex. 12				H, R
PTX 322	Velturo Ex. 12-A				H, R
PTX 323	Velturo Ex. 12-B				H, R
PTX 324	Velturo Ex. 7-B				H, R
PTX 325	Velturo Ex. 7-C				H, R
PTX 326	Velturo Ex. 7-A				H, R
PTX 327	Velturo Ex.8-C				H, R
PTX 328	Velturo Ex. 8-A				H, R
PTX 329	Velturo Ex.8-B				H, R
PTX 330	Velturo Ex. 5				H, R
PTX 331	Velturo Ex. 6				H, R
PTX 332	Velturo Ex. 5-A				H, R
PTX 333	Velturo Ex. 6-A				H, R
PTX 334	Velturo Ex. 13				H, R
PTX 335	GSK-REQ061860	GSK-REQ061861			A, H, R
PTX 336	GSK-VEL 000135	GSK-VEL 000135			
PTX 337	GSK-VEL 000136	GSK-VEL 000138			R, IN
PTX 338	GSK-VEL 000234	GSK-VEL 000235			R, IN
PTX 339	GSK-VEL 000463	GSK-VEL 000464			M
PTX 340	GSK-VEL 000152	GSK-VEL 000153			
PTX 341	GSK-VEL 000044	GSK-VEL 000070			
PTX 342	GSK-VEL 000208	GSK-VEL 000213			A, H, R, IN
PTX 343	GSK-VEL 000236	GSK-VEL 000237			A, H, IN, MI
PTX 344	GSK-VEL 000461	GSK-VEL 000462			M
PTX 345	Velturo Ex. 10-A				H, R
PTX 346	GSK-VEL 000642	GSK-VEL 000642			M
PTX 347	GSK-SUD 000065	GSK-SUD 000086			R

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 348	GSK-REQ 088816	GSK-REQ 088825			H, R
PTX 349	GSK-REQ 025995	GSK-REQ 025996			H, R
PTX 350	GSK-REQ 025827	GSK-REQ 025831			H, R
PTX 351	Vellituro Ex. 9				A, H, R
PTX 352	GSK-REQ 090676	GSK-REQ 090689			H, R
PTX 353	GSK-SUD 000126	GSK-SUD 000162			
PTX 354	GSK-REQ 063862	GSK-REQ 063867			H, R, IN
PTX 355	GSK-REQ 057656	GSK-REQ 057659			H, R, IN
PTX 356	Vellituro Ex. 2				H, R
PTX 357	GSK-VEL 000246	GSK-VEL 000248			M
PTX 358	GSK-REQ 020979	GSK-REQ 020979	2001		M
PTX 359	GSK-REQ 020980	GSK-REQ 021018	02/05/2001		A, H, R, IL
PTX 360	GSK-REQ 021019	GSK-REQ 021075	06/22/1905		H, R
PTX 361	GSK-REQ 021141	GSK-REQ 021166			H, R, IN
PTX 362	GSK-REQ 021167	GSK-REQ 021193			H, R, IN
PTX 363	GSK-REQ 025074	GSK-REQ 025075			IL, IN, A, H, R, MI
PTX 364	GSK-REQ 025076	GSK-REQ 025160	7/26/2000		H, R
PTX 365	GSK-REQ 025161	GSK-REQ 025216			H, R
PTX 366	GSK-REQ 025217	GSK-REQ 025291	Jan-01		H, R
PTX 367	GSK-REQ 025292	GSK-REQ 025347	2001		H, R
PTX 368	GSK-REQ 025348	GSK-REQ 025393	8/21/2002		H, R, MI
PTX 369	GSK-REQ 025394	GSK-REQ 025444	Oct-02		H, R, MI
PTX 370	GSK-REQ 025445	GSK-REQ 025499	Oct-02		H, R, MI
PTX 371	GSK-REQ 025500	GSK-REQ 025551	2-Oct		H, R, MI
PTX 372	GSK-REQ 025552	GSK-REQ 025593	8/21/2002		H, R, MI
PTX 373	GSK-REQ 025594	GSK-REQ 025620	8/21/2002		H, R, MI
PTX 374	GSK-REQ 025621	GSK-REQ 025630			A, H, R, IN, MI
PTX 375	GSK-REQ 025631	GSK-REQ 025673			H, R
PTX 376	GSK-REQ 025674	GSK-REQ 025739			H, R
PTX 377	GSK-REQ 025740	GSK-REQ 025774	2003		H, R
PTX 378	GSK-REQ 025775	GSK-REQ 025787			H, IN, R
PTX 379	GSK-REQ 025788	GSK-REQ 025788			H, R, B
PTX 380	GSK-REQ 025789	GSK-REQ 025789			H, R, B
PTX 381	GSK-REQ 025790	GSK-REQ 025795			H, R, MI, IN
PTX 382	GSK-REQ 025796	GSK-REQ 025802			H, R, B,
PTX 383	GSK-REQ 025803	GSK-REQ 025804			H, R, IL, B
PTX 384	GSK-REQ 025805	GSK-REQ 025806			A, H, R, B, IL
PTX 385	GSK-REQ 025807	GSK-REQ 025807			H, R, IN
PTX 386	GSK-REQ 025808	GSK-REQ 025808			A, H, R, IN, MI
PTX 387	GSK-REQ 025809	GSK-REQ 025809			A, H, R, IL, MI
PTX 388	GSK-REQ 025810	GSK-REQ 025810			A, H, R, IL, MI
PTX 389	GSK-REQ 025811	GSK-REQ 025817	4/21/2001		A, H, R, B, MI
PTX 390	GSK-REQ 025818	GSK-REQ 025826			H, R
PTX 391	GSK-REQ 025832	GSK-REQ 025841			H, R, IL
PTX 392	GSK-REQ 025842	GSK-REQ 025844			A, H, R
PTX 393	GSK-REQ 025845	GSK-REQ 025846			H, R
PTX 394	GSK-REQ 025847	GSK-REQ 025858			H, R
PTX 395	GSK-REQ 025859	GSK-REQ 025868			H, R, IL
PTX 396	GSK-REQ 025869	GSK-REQ 025870			H, R
PTX 397	GSK-REQ 025871	GSK-REQ 025871			A, H, R, B, MI
PTX 398	GSK-REQ 025872	GSK-REQ 025872			A, H, R, B, MI
PTX 399	GSK-REQ 025873	GSK-REQ 025877			H, R, IN
PTX 400	GSK-REQ 025878	GSK-REQ 025879			H, R, IL

EXHIBIT 8 TO PROPOSED PRETRIAL ORDER**TEVA'S DRAFT OBJECTIONS TO GSK'S DRAFT EXHIBIT LIST**

Plaintiff's Trial Exhibit No.	Beginning Bates	Ending Bates	Date (if indicated on document)	Description	Objections
PTX 401	GSK-REQ 025880	GSK-REQ 025886			H, R, IL
PTX 402	GSK-REQ 025887	GSK-REQ 025887			H, R, IL
PTX 403	GSK-REQ 025888	GSK-REQ 025888			H, R, IL
PTX 404	GSK-REQ 025889	GSK-REQ 025952			H, R, IL
PTX 405	GSK-REQ 025953	GSK-REQ 025960			B, A, H, R
PTX 406	GSK-REQ 025961	GSK-REQ 025961			H, R, IL
PTX 407	GSK-REQ 025962	GSK-REQ 025991			H, R, B, MD, MI
PTX 408	GSK-REQ 025992	GSK-REQ 025992			H, R, B
PTX 409	GSK-REQ 025993	GSK-REQ 025994			H, R, B
PTX 410	GSK-REQ 025995	GSK-REQ 025996			H, R, IL
PTX 411	GSK-REQ 025997	GSK-REQ 025997			H, R, B
PTX 412	GSK-REQ 025998	GSK-REQ 025999			H, R, B
PTX 413	GSK-REQ 136060	GSK-REQ 136069			H, R, IN A, MI, MD, T
PTX 414	GSK-BER 000616	GSK-BER 000631	10/22/1986		R, F, IL
PTX 415	GSK-BER 000632	GSK-BER 000639	12/23/1992		R, F, IL
PTX 416			9/22/2006		H, R
PTX 417			9/22/2006		H, R
PTX 418			9/22/2006		H, R
PTX 419	http://www.fda.gov/cder/foi/appltr/2005/020658s013ltr.pdf		5/4/2005		T, H, R
PTX 420	GSK-VEL 000269	GSK-VEL 000269			H, R, T, MI, MD
PTX 421	GSK-VEL 000641	GSK-VEL 000641			H, R, T, MI, MD
PTX 422	GSK-REQ 011531	GSK-REQ 011531	9/9/1998		H, R
PTX 423	http://www.fda.gov/CDER/foi/nda/97/020658a_p_requip_apltr.pdf		9/19/1997		H, R
PTX 424	GSK-BAR 000107	GSK-BAR 000115			R
PTX 425					M
PTX 426					R
PTX 427					R, IN, MI
PTX 428					M
PTX 429					M
PTX 430					M
PTX 431			2006		M
PTX 432	TEV-RQEXP000349	TEV-RQEXP000355	2001		

EXHIBIT 9 TO PRETRIAL ORDER**UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF DELAWARE**

AO 187

SMITH KLINE & FRENCH LABORATORIES, LTD. AND SMITHKLINE BEECHAM CORP., D/B/A GLAXOSMITHKLINE, Plaintiffs, v. TEVA PHARMACEUTICALS USA, INC., Defendant.		EXHIBIT LIST Case No. 05-197 (GMS)
PRESIDING JUDGE: Honorable Gregory M. Sleet	PLAINTIFFS' ATTORNEYS:	DEFENDANT'S ATTORNEYS: Jay Lefkowitz Edward C. Donovan
TRIAL DATES: 12/18/2006 - 12/22/2006	COURT REPORTER:	COURTROOM DEPUTY:

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 1				
	DTX 2				
	DTX 3				
	DTX 4				
	DTX 5				
	DTX 6				
	DTX 7				
	DTX 8				
	DTX 9				
	DTX 10				
	DTX 11				
	DTX 12				

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 13				
	DTX 14				
	DTX 15				
	DTX 16				
	DTX 17				
	DTX 18				
	DTX 19				[REDACTED]
	DTX 20				[REDACTED]
	DTX 21				[REDACTED]
	DTX 22				[REDACTED]
	DTX 23				[REDACTED]
	DTX 24				[REDACTED]
	DTX 25				[REDACTED]
	DTX 26				[REDACTED]
	DTX 27				[REDACTED]
	DTX 28				[REDACTED]
	DTX 29				[REDACTED]
	DTX 30				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 31				[REDACTED]
	DTX 32				[REDACTED]
	DTX 33				[REDACTED]
	DTX 34				[REDACTED]
	DTX 35				[REDACTED]
	DTX 36				[REDACTED]
	DTX 37				[REDACTED]
	DTX 38				[REDACTED]
	DTX 39				[REDACTED]
	DTX 40				[REDACTED]
	DTX 41				[REDACTED]
	DTX 42				[REDACTED]
	DTX 43				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 44				[REDACTED]
	DTX 45				[REDACTED]
	DTX 46				[REDACTED]
	DTX 47				[REDACTED]
	DTX 48				[REDACTED]
	DTX 49				[REDACTED]
	DTX 50				[REDACTED]
	DTX 51				[REDACTED]
	DTX 52				[REDACTED]
	DTX 53				[REDACTED]
	DTX 54				[REDACTED]
	DTX 55				[REDACTED]
	DTX 56				[REDACTED]
	DTX 57				[REDACTED]
	DTX 58				[REDACTED]
	DTX 59				[REDACTED]
	DTX 60				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 61				[REDACTED]
	DTX 62				[REDACTED]
	DTX 63				[REDACTED]
	DTX 64				[REDACTED]
	DTX 65				[REDACTED]
	DTX 66				[REDACTED]
	DTX 67				[REDACTED]
	DTX 68				[REDACTED]
	DTX 69				[REDACTED]
	DTX 70				[REDACTED]
	DTX 71				[REDACTED]
	DTX 72				[REDACTED]
	DTX 73				[REDACTED]
	DTX 74				[REDACTED]
	DTX 75				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 76				[REDACTED]
	DTX 77				[REDACTED]
	DTX 78				[REDACTED]
	DTX 79				[REDACTED]
	DTX 80				[REDACTED]
	DTX 81				[REDACTED]
	DTX 82				[REDACTED]
	DTX 83				[REDACTED]
	DTX 84				[REDACTED]
	DTX 85				[REDACTED]
	DTX 86				[REDACTED]
	DTX 87				[REDACTED]
	DTX 88				[REDACTED]
	DTX 89				[REDACTED]
	DTX 90				[REDACTED]
	DTX 91				[REDACTED]
	DTX 92				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 93				[REDACTED]
	DTX 94				[REDACTED]
	DTX 95				[REDACTED]
	DTX 96				[REDACTED]
	DTX 97				[REDACTED]
	DTX 98				[REDACTED]
	DTX 99				[REDACTED]
	DTX 100				[REDACTED]
	DTX 101				[REDACTED]
	DTX 102				[REDACTED]
	DTX 103				[REDACTED]
	DTX 104				[REDACTED]
	DTX 105				[REDACTED]
	DTX 106				[REDACTED]
	DTX 107				[REDACTED]
	DTX 108				[REDACTED]
	DTX 109				[REDACTED]
	DTX 110				[REDACTED]
	DTX 111				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 112				[REDACTED]
	DTX 113				[REDACTED]
	DTX 114				[REDACTED]
	DTX 115				[REDACTED]
	DTX 116				[REDACTED]
	DTX 117				[REDACTED]
	DTX 118				[REDACTED]
	DTX 119				[REDACTED]
	DTX 120				[REDACTED]
	DTX 121				[REDACTED]
	DTX 122				[REDACTED]
	DTX 123				[REDACTED]
	DTX 124				[REDACTED]
	DTX 125				[REDACTED]
	DTX 126				[REDACTED]
	DTX 127				[REDACTED]
	DTX 128				[REDACTED]
	DTX 129				[REDACTED]
	DTX 130				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 131				[REDACTED]
	DTX 132				[REDACTED]
	DTX 133				[REDACTED]
	DTX 134				[REDACTED]
	DTX 135				[REDACTED]
	DTX 136				[REDACTED]
	DTX 137				[REDACTED]
	DTX 138				[REDACTED]
	DTX 139				[REDACTED]
	DTX 140				[REDACTED]
	DTX 141				[REDACTED]
	DTX 142				[REDACTED]
	DTX 143				[REDACTED]
	DTX 144				[REDACTED]
	DTX 145				[REDACTED]
	DTX 146				[REDACTED]
	DTX 147				[REDACTED]
	DTX 148				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 149				[REDACTED]
	DTX 150				[REDACTED]
	DTX 151				[REDACTED]
	DTX 152				[REDACTED]
	DTX 153				[REDACTED]
	DTX 154				[REDACTED]
	DTX 155				[REDACTED]
	DTX 156				[REDACTED]
	DTX 157				[REDACTED]
	DTX 158				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 159				[REDACTED]
	DTX 160				[REDACTED]
	DTX 161				[REDACTED]
	DTX 162				[REDACTED]
	DTX 163				[REDACTED]
	DTX 164				[REDACTED]
	DTX 165				[REDACTED]
	DTX 166				[REDACTED]
	DTX 167				[REDACTED]
	DTX 168				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 169				[REDACTED]
	DTX 170				[REDACTED]
	DTX 171				[REDACTED]
	DTX 172				[REDACTED]
	DTX 173				[REDACTED]
	DTX 174				[REDACTED]
	DTX 175				[REDACTED]
	DTX 176				[REDACTED]
	DTX 177				[REDACTED]
	DTX 178				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 179				[REDACTED]
	DTX 180				[REDACTED]
	DTX 181				[REDACTED]
	DTX 182				[REDACTED]
	DTX 183				[REDACTED]
	DTX 184				[REDACTED]
	DTX 185				[REDACTED]
	DTX 186				[REDACTED]
	DTX 187				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 188				[REDACTED]
	DTX 189				[REDACTED]
	DTX 190				[REDACTED]
	DTX 191				[REDACTED]
	DTX 192				[REDACTED]
	DTX 193				[REDACTED]
	DTX 194				[REDACTED]
	DTX 195				[REDACTED]
	DTX 196				[REDACTED]
	DTX 197				[REDACTED]
	DTX 198				[REDACTED]
	DTX 199				[REDACTED]
	DTX 200				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 201				[REDACTED]
	DTX 202				[REDACTED]
	DTX 203				[REDACTED]
	DTX 204				[REDACTED]
	DTX 205				[REDACTED]
	DTX 206				[REDACTED]
	DTX 207				[REDACTED]
	DTX 208				[REDACTED]
	DTX 209				[REDACTED]
	DTX 210				[REDACTED]
	DTX 211				[REDACTED]
	DTX 212				[REDACTED]
	DTX 213				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 214				[REDACTED]
	DTX 215				[REDACTED]
	DTX 216				[REDACTED]
	DTX 217				[REDACTED]
	DTX 218				[REDACTED]
	DTX 219				[REDACTED]
	DTX 220				[REDACTED]
	DTX 221				[REDACTED]
	DTX 222				[REDACTED]
	DTX 223				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 224				[REDACTED]
	DTX 225				[REDACTED]
	DTX 226				[REDACTED]
	DTX 227				[REDACTED]
	DTX 228				[REDACTED]
	DTX 229				[REDACTED]
	DTX 230				[REDACTED]
	DTX 231				[REDACTED]
	DTX 232				[REDACTED]
	DTX 233				[REDACTED]
	DTX 234				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 235				[REDACTED]
	DTX 236				[REDACTED]
	DTX 237				[REDACTED]
	DTX 238				[REDACTED]
	DTX 239				[REDACTED]
	DTX 240				[REDACTED]
	DTX 241				[REDACTED]
	DTX 242				[REDACTED]
	DTX 243				[REDACTED]
	DTX 244				[REDACTED]
	DTX 245				[REDACTED]
	DTX 246				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 247				[REDACTED]
	DTX 248				[REDACTED]
	DTX 249				[REDACTED]
	DTX 250				[REDACTED]
	DTX 251				[REDACTED]
	DTX 252				[REDACTED]
	DTX 253				[REDACTED]
	DTX 254				[REDACTED]
	DTX 255				[REDACTED]
	DTX 256				[REDACTED]
	DTX 257				[REDACTED]
	DTX 258				[REDACTED]
	DTX 259				[REDACTED]
	DTX 260				[REDACTED]
	DTX 261				[REDACTED]
	DTX 262				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 263				[REDACTED]
	DTX 264				[REDACTED]
	DTX 265				[REDACTED]
	DTX 266				[REDACTED]
	DTX 267				[REDACTED]
	DTX 268				[REDACTED]
	DTX 269				[REDACTED]
	DTX 270				[REDACTED]
	DTX 271				[REDACTED]
	DTX 272				[REDACTED]
	DTX 273				[REDACTED]
	DTX 274				[REDACTED]
	DTX 275				[REDACTED]
	DTX 276				[REDACTED]
	DTX 277				[REDACTED]
	DTX 278				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 279				[REDACTED]
	DTX 280				[REDACTED]
	DTX 281				[REDACTED]
	DTX 282				[REDACTED]
	DTX 283				[REDACTED]
	DTX 284				[REDACTED]
	DTX 285				[REDACTED]
	DTX 286				[REDACTED]
	DTX 287				[REDACTED]
	DTX 288				[REDACTED]
	DTX 289				[REDACTED]
	DTX 290				[REDACTED]
	DTX 291				[REDACTED]
	DTX 292				[REDACTED]
	DTX 293				[REDACTED]
	DTX 294				[REDACTED]
	DTX 295				[REDACTED]
	DTX 296				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 297				[REDACTED]
	DTX 298				[REDACTED]
	DTX 299				[REDACTED]
	DTX 300				[REDACTED]
	DTX 301				[REDACTED]
	DTX 302				[REDACTED]
	DTX 303				[REDACTED]
	DTX 304				[REDACTED]
	DTX 305				[REDACTED]
	DTX 306				[REDACTED]
	DTX 307				[REDACTED]
	DTX 308				[REDACTED]
	DTX 309				[REDACTED]
	DTX 310				[REDACTED]
	DTX 311				[REDACTED]
	DTX 312				[REDACTED]
	DTX 313				[REDACTED]
	DTX 314				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 315				[REDACTED]
	DTX 316				[REDACTED]
	DTX 317				[REDACTED]
	DTX 318				[REDACTED]
	DTX 319				[REDACTED]
	DTX 320				[REDACTED]
	DTX 321				[REDACTED]
	DTX 322				[REDACTED]
	DTX 323				[REDACTED]
	DTX 324				[REDACTED]
	DTX 325				[REDACTED]
	DTX 326				[REDACTED]
	DTX 327				[REDACTED]
	DTX 328				[REDACTED]
	DTX 329				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 330				[REDACTED]
	DTX 331				[REDACTED]
	DTX 332				[REDACTED]
	DTX 333				[REDACTED]
	DTX 334				[REDACTED]
	DTX 335				[REDACTED]
	DTX 336				[REDACTED]
	DTX 337				[REDACTED]
	DTX 338				[REDACTED]
	DTX 339				[REDACTED]
	DTX 340				[REDACTED]
	DTX 341				[REDACTED]
	DTX 342				[REDACTED]
	DTX 343				[REDACTED]
	DTX 344				[REDACTED]
	DTX 345				[REDACTED]
	DTX 346				[REDACTED]
	DTX 347				[REDACTED]
	DTX 348				[REDACTED]
	DTX 349				[REDACTED]
	DTX 350				[REDACTED]

Plf. No.	Def. No.	Date Offered	Marked	Admitted	Description of Exhibits and Witnesses
	DTX 351				[REDACTED]
	DTX 352				[REDACTED]
	DTX 353				[REDACTED]
	DTX 354				[REDACTED]
	DTX 355				[REDACTED]
	DTX 356				[REDACTED]
	DTX 357				[REDACTED]
	DTX 358				[REDACTED]
	DTX 359				[REDACTED]
	DTX 360				[REDACTED]
	DTX 361				[REDACTED]
	DTX 362				[REDACTED]
	DTX 363				[REDACTED]
	DTX 364				[REDACTED]

Teva provides this initial exhibit list pursuant to the parties' agreement to jointly prepare an exhibit list in compliance with the Court's standing order for final pre-trial orders. Teva's initial list provided to plaintiffs is without prejudice to Teva's right to object to the admissibility of any exhibit if offered by plaintiffs, including exhibits appearing on Teva's initial exhibit list. Teva reserves the right to amend this list as circumstances may warrant, including as a result of expert discovery.